<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996840</url>
  </required_header>
  <id_info>
    <org_study_id>111592</org_study_id>
    <nct_id>NCT00996840</nct_id>
  </id_info>
  <brief_title>SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS</brief_title>
  <official_title>Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre
      study for subjects with trauma (physical injury) who are at risk for developing Acute Lung
      Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The primary purpose of the study
      is to evaluate the safety and tolerability of SB-681323, which is a potent, selective
      inhibitor of p38 alpha (MAPK) (prevents inflammation of tissue), in comparison to a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The acute respiratory distress syndrome (ARDS) is a form of severe lung injury (ALI)
      characterized by hypoxemic respiratory failure (the lungs are unable to absorb oxygen to the
      arterial blood) and non-cardiogenic pulmonary edema (accumulation of fluid in the lungs). The
      syndrome may be caused by direct or indirect injury to the lungs. It is associated with a
      mortality rate of up to 40-50%. There are no marketed pharmacologic therapies for this
      devastating syndrome.

      This study aims to assess the safety and tolerability of SB-681323, which is a potent,
      selective inhibitor of p38 alpha mitogen-activated protein kinase.

      The rationale behind the development of this drug is that there are elevated levels of
      circulating pro-inflammatory agents, such as cytokines which are biological agents that
      increase levels of inflammation in the lungs. These agents are part of an 'inflammatory loop'
      and it may be beneficial to the condition to dampen this loop.

      p38 mitogen activated protein kinase (MAPK) plays a major role in the regulation and
      activation of intracellular proteins which are subsequently involved in the regulation of the
      cytokines. The pathway is activated by 'stress', such as injury, causing the inflammation.
      Therefore, 'dampening' this system should reduce the level of inflammation.

      This study will investigate the anti-inflammatory activity, efficacy (effectiveness at
      achieving the desired effect) and safety of SB-681323.

      To measure the efficacy of the drug, biomarkers will be measured. Biomarkers are biological
      agents in the body that are effected by the presence of specific injury or inflammation and
      are directly or indirectly linked to a regulatory system of event in the body. They are used
      to measure for the presence and severity of the condition in question. This study will
      investigate biomarkers linked directly or indirectly to the p38 alpha regulatory
      mechanism/system. We will be measuring biomarkers such as serum inflammatory biomarkers,
      coagulation (blood clotting) system biomarkers, biomarkers of endothelial cell / neutrophil
      interaction and biomarkers of lung epithelial cell injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2009</start_date>
  <completion_date type="Actual">February 9, 2013</completion_date>
  <primary_completion_date type="Actual">February 9, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Mean hematology parameters including basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, white blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Hematology Parameters- Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Mean hematology parameters including hemoglobin, MCHC were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Hematology Parameters- Mean Corpuscle Hemoglobin</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Hematology parameter mean corpuscle hemoglobin was reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology Parameters-Mean Corpuscle Volume</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of mean corpuscle volume were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Hematology Parameters-reticulocytes, Red Blood Cell Count</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of reticulocytes and red blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Clinical Chemistry Parameters- Albumin and Total Protein</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of albumin and total protein were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Clinical Chemistry Parameters-alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase and Gamma Glutamyl Transferase</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and gamma glutamyl transferase were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Clinical Chemistry Parameters- Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of direct bilirubin, total bilirubin, creatinine and uric acid were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Clinical Chemistry Parameters- Calcium, Chloride, Glucose, Bicarbonate, Potassium, Sodium and Ratio of Urea to Blood Urea Nitrogen (Urea/BUN)</measure>
    <time_frame>&quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of calcium, chloride, glucose, bicarbonate, potassium, sodium and Urea/BUN were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Clinical Chemistry Parameters-estradiol</measure>
    <time_frame>Day 1 (pre-dose) and Day 3 (24 h)</time_frame>
    <description>Absolute values of Estradiol were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Clinical Chemistry Parameters-Blood pH at Screening</measure>
    <time_frame>Screening</time_frame>
    <description>Absolute values of Blood pH at screening were reported as clinical chemistry parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Parameter- Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot; and &quot;Follow up (Day 7)&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;, and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of SBP and DBP were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Parameter: Mean Heart Rate</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot; and &quot;Follow up (Day 7)&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;, and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of mean heart rate were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Sign: Mean Percent Oxygen (O2) in Blood</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot; and &quot;Follow up (Day 7)&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;, and &quot;Follow up (Day 7)&quot;</time_frame>
    <description>Absolute values of mean percent O2 in blood were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Mean Oxygen Saturation (SaO2) Via Pulse Oximetry</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, and &quot;Day 3, pre-dose and 24 h&quot;</time_frame>
    <description>Assessment of SaO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Mean Level of Positive End Expiratory Pressure</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, and &quot;Day 3, pre-dose and 24 h&quot;</time_frame>
    <description>Assessment of level of positive end expiratory pressure was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Mean Level of Peak and Plateau Ventilator Pressures</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, and &quot;Day 3, pre-dose and 24 h&quot;</time_frame>
    <description>Assessment of mean level of peak and plateau ventilator pressures was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs: Mean Oxygen Requirement (FiO2) Via Pulse Oximetry</measure>
    <time_frame>For Cohort 1 and 3: &quot;Day 1, 4 h&quot;, &quot;Day 2, pre-dose&quot;, &quot;Day 3, pre-dose and 24 h&quot;; for Cohort 2 and 4: &quot;Day 2, pre-dose&quot;, and &quot;Day 3, pre-dose and 24 h&quot;</time_frame>
    <description>Assessment of mean FiO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Electrocardiogram (ECG) Parameters Including PR, QRS, QT, and QTcB, QTcF, RR Intervals</measure>
    <time_frame>Day 2, pre-dose, Day 3, pre-dose, Day 3, 24 h and Follow-up (Day 7)</time_frame>
    <description>12-lead ECGs were obtained at each timepoint during the study using an ECG machine that automatically calculated the heart rate and measures RR, PR, QRS, QT, and QTc intervals. Absolute mean values of PR, QRS, QT, and QTcB, QTcF, RR intervals were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>Up to Follow-up (Day 7)</time_frame>
    <description>AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Interleukin-6 Levels</measure>
    <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
    <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum interleukin-6 levels at these specified time oints were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum CXCL8 (Interleuin-8) Levels</measure>
    <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
    <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum CXCL8 (Interleuin-8) levels at these specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum C-Reactive Protein (CRP) Levels</measure>
    <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
    <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of serum CRP levels at these specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Endothelial Cell/Neutrophil Interaction: Mean Soluble Tumor Necrosis Factor Receptors-I</measure>
    <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
    <description>Samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of soluble tumor necrosis factor receptors-I levels at these specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Lung Epithelial Cell Injury: Mean Myeloperoxidase (MPO) Levels</measure>
    <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
    <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of MPO levels at these specified time points were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC0-24)</measure>
    <time_frame>For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose)</time_frame>
    <description>Absolute values of the mean AUC 0-24 of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h10minutes [min], 24h45min, 27, 34, 40, 80 h since doing on Day 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Average Concentration (Cavg) of SB-681323</measure>
    <time_frame>For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10minutes [min], 24h 45min, 27, 34, 40, 80 h since doing on Day 3)</time_frame>
    <description>Absolute values of mean Cavg of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of SB-681323</measure>
    <time_frame>For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3)</time_frame>
    <description>Absolute values of the Cmax of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Lung Injury, Acute</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - SB-681323 Intravenous 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg SB-681323 Intravenous administration, infused over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - SB-681323 Intravenous 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg SB-681323 Intravenous administration infused over 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - SB-681323 Intravenous 7.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg SB-681323 Intravenous administration infused over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - SB-681323 Intravenous 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg SB-681323 Intravenous administration infused over 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to match intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-681323 Intravenous 3mg</intervention_name>
    <description>3 mg SB-681323 Intravenous administration infused over 4 hours</description>
    <arm_group_label>Cohort 1 - SB-681323 Intravenous 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-681323 Intravenous 7.5 mg</intervention_name>
    <description>7.5 mg SB-681323 Intravenous administration infused over 24 hours</description>
    <arm_group_label>Cohort 2 - SB-681323 Intravenous 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-681323 Intravenous 7.5mg</intervention_name>
    <description>7.5 mg SB-681323 Intravenous administration infused over 4 hours</description>
    <arm_group_label>Cohort 3 - SB-681323 Intravenous 7.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-681323 Intravenous 10mg</intervention_name>
    <description>10 mg SB-681323 Intravenous administration infused over 24 hours</description>
    <arm_group_label>Cohort 4 - SB-681323 Intravenous 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match intervention</description>
    <arm_group_label>Combined Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject will be eligible for inclusion in this study only if all of the following
        criteria apply:

          -  Male or female, 18 - 80 years of age (inclusive) with major trauma admitted to the
             Intensive Care Unit (ICU).

          -  Injury Severity score (ISS) &gt;16 to &lt;70 (exclusive)

          -  A female subject is eligible to participate if she is of non-child-bearing potential
             or of:

          -  Child-bearing potential and agrees to use one of the approved contraception methods
             (oral contraceptive, either combined or progesterone alone, injectable progesterone,
             implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive
             patches, intrauterine device (IUD) or intrauterine system (IUS) with less than 1%
             non-effectiveness, documented male partner sterilization, double barrier method, i.e.
             condom and occlusive cap plus spermicidal agent) for an appropriate period of time (as
             determined by the product label or investigator, if applicable. Female subjects must
             agree to use contraception until one week post-last dose, if applicable.

          -  Male subjects must agree to use one of the approved contraception methods (abstinence,
             defined as sexual inactivity consistent with the preferred and usual lifestyle of the
             subject, condom during non-vaginal intercourse with any partner (male or female),
             condom and occlusive cap plus spermicidal agent during sexual intercourse with a
             female) if applicable. This criterion must be followed from the time of the first dose
             of study medication until one week post-last dose, if applicable.

          -  BMI within the range 19.0 - 35.0 kg/m2 inclusive (clinical estimate of height and
             weight is acceptable).

          -  The subject or legal decision maker is capable of giving written informed consent,
             which includes compliance with the requirements and restrictions listed in the consent
             form.

          -  QTcB or QTcF &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block.

          -  The subject must be randomized into the study within 24-26 hours from the time of
             trauma.

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  Known positive Hepatitis B surface antigen or Hepatitis C antibody.

          -  Known positive test for HIV antibody.

          -  A known history of substance abuse, alcohol abuse, or regular alcohol consumption
             within 6 months of the study defined as:

          -  an average weekly intake of greater than 21 units or an average daily intake of
             greater than 3 units (males), or defined as an average weekly intake of greater than
             14 units or an average daily intake of greater than 2 units (females). One unit is
             equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass
             (125ml) of wine.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  History of sensitivity to any of the study medications, or components thereof, or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Haemoglobin &lt; 7g/dL.

          -  Pregnant females as determined by positive serum or urine hCG test prior to dosing.

          -  Lactating females.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Diagnosis of ALI at admission.

          -  Head trauma (Abbreviated Injury Score [AIS]&gt;3), liver trauma (AIS&gt;2), or trauma that
             in the opinion of the Principle Investigator or GSK medical monitor is deemed
             unsurvivable.

          -  Known history of neuromuscular disease or cord injury at C5 or above.

          -  Elevated ALT or AST &gt; 1.5 ULN.

          -  History of bone marrow or solid organ transplant.

          -  Known history of auto-immune disorder in which immunosuppressive agents, other than
             prednisone, were required within the last 6 weeks.

          -  Known to be receiving oral or intravenous corticosteroids within 7 days of admission.

          -  Subject with active tuberculosis or being treated for active tuberculosis.

          -  Known history of malignancy within the past 5 years with the exception of successfully
             treated squamous cell or basal cell cancer of the skin.

          -  Arterial blood pH less than 7.1 or serum HCO3 - &lt;15 before infusion is started.

          -  Persistent cardiovascular instability requiring therapy with more than one
             vasopressor.

          -  A patient will be excluded if in the judgement of the Principle Investigator or GSK
             medical monitor their participation could jeopardize the health of the subject or the
             integrity of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-7110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <results_first_submitted>August 4, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2017</results_first_posted>
  <disposition_first_submitted>April 27, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 13, 2015</disposition_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dilmapimod</keyword>
  <keyword>p38</keyword>
  <keyword>SB-681323</keyword>
  <keyword>Acute Lung Injury (ALI)</keyword>
  <keyword>Acute Respiratory Distress Syndrome (ARDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111592</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted across 6 centers in the United States, with 5 centers actually enrolling participants. The first participant was enrolled on 16-October-2009 and the last participant completed the study on 09-February-2013.</recruitment_details>
      <pre_assignment_details>Seventy seven participants were randomized in the study and were included in All subject population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Placebo</title>
          <description>Eligible participants received matching placebo intravenous (IV) infusion over 4 hours (h) or 24 h for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
          <description>Eligible participants received SB-681323, 3 milligrams (mg), IV infusion over 4h for 3 days</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
          <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
          <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
        </group>
        <group group_id="P5">
          <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
          <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Placebo</title>
          <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
          <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
          <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
          <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
        </group>
        <group group_id="B5">
          <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
          <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="18"/>
            <count group_id="B6" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" spread="17.70"/>
                    <measurement group_id="B2" value="47.4" spread="19.31"/>
                    <measurement group_id="B3" value="34.5" spread="15.61"/>
                    <measurement group_id="B4" value="44.1" spread="15.89"/>
                    <measurement group_id="B5" value="46.1" spread="21.80"/>
                    <measurement group_id="B6" value="42.7" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count</title>
        <description>Mean hematology parameters including basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, white blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject Population comprised of as all participant who received at least one dose of study medication. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count</title>
          <description>Mean hematology parameters including basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, white blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject Population comprised of as all participant who received at least one dose of study medication. Only those participants available at the specified time points were analyzed.</population>
          <units>Giga cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0305" spread="0.04196"/>
                    <measurement group_id="O2" value="0.0163" spread="0.01188"/>
                    <measurement group_id="O3" value="0.0208" spread="0.02843"/>
                    <measurement group_id="O4" value="0.0153" spread="0.01125"/>
                    <measurement group_id="O5" value="0.0258" spread="0.02134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0291" spread="0.03036"/>
                    <measurement group_id="O2" value="0.0129" spread="0.00756"/>
                    <measurement group_id="O3" value="0.0209" spread="0.02737"/>
                    <measurement group_id="O4" value="0.0176" spread="0.01562"/>
                    <measurement group_id="O5" value="0.0279" spread="0.03191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0239" spread="0.02062"/>
                    <measurement group_id="O2" value="0.0294" spread="0.02809"/>
                    <measurement group_id="O3" value="0.0300" spread="0.02374"/>
                    <measurement group_id="O4" value="0.0284" spread="0.02762"/>
                    <measurement group_id="O5" value="0.0315" spread="0.04240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0389" spread="0.03660"/>
                    <measurement group_id="O2" value="0.0314" spread="0.02340"/>
                    <measurement group_id="O3" value="0.0300" spread="0.02625"/>
                    <measurement group_id="O4" value="0.0345" spread="0.03965"/>
                    <measurement group_id="O5" value="0.0240" spread="0.02501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0968" spread="0.18817"/>
                    <measurement group_id="O2" value="0.0676" spread="0.07149"/>
                    <measurement group_id="O3" value="0.0633" spread="0.07451"/>
                    <measurement group_id="O4" value="0.0331" spread="0.04319"/>
                    <measurement group_id="O5" value="0.0724" spread="0.07411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1588" spread="0.18027"/>
                    <measurement group_id="O2" value="0.0894" spread="0.06882"/>
                    <measurement group_id="O3" value="0.0964" spread="0.10112"/>
                    <measurement group_id="O4" value="0.0746" spread="0.06376"/>
                    <measurement group_id="O5" value="0.0664" spread="0.04955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2544" spread="0.18852"/>
                    <measurement group_id="O2" value="0.1538" spread="0.07558"/>
                    <measurement group_id="O3" value="0.1400" spread="0.14365"/>
                    <measurement group_id="O4" value="0.1345" spread="0.12560"/>
                    <measurement group_id="O5" value="0.1142" spread="0.07005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3713" spread="0.29748"/>
                    <measurement group_id="O2" value="0.2866" spread="0.25120"/>
                    <measurement group_id="O3" value="0.1900" spread="0.16445"/>
                    <measurement group_id="O4" value="0.2390" spread="0.08483"/>
                    <measurement group_id="O5" value="0.1998" spread="0.14855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2943" spread="0.68932"/>
                    <measurement group_id="O2" value="0.9725" spread="0.43980"/>
                    <measurement group_id="O3" value="1.0575" spread="0.49116"/>
                    <measurement group_id="O4" value="1.3276" spread="0.57791"/>
                    <measurement group_id="O5" value="1.5365" spread="0.83119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2594" spread="0.59834"/>
                    <measurement group_id="O2" value="1.0103" spread="0.39949"/>
                    <measurement group_id="O3" value="1.0582" spread="0.42171"/>
                    <measurement group_id="O4" value="1.1462" spread="0.52784"/>
                    <measurement group_id="O5" value="1.1593" spread="0.55383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1146" spread="0.44206"/>
                    <measurement group_id="O2" value="1.0406" spread="0.36407"/>
                    <measurement group_id="O3" value="1.0067" spread="0.60161"/>
                    <measurement group_id="O4" value="1.1936" spread="0.50190"/>
                    <measurement group_id="O5" value="1.4288" spread="0.62231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4967" spread="0.53371"/>
                    <measurement group_id="O2" value="1.0611" spread="0.31455"/>
                    <measurement group_id="O3" value="1.0370" spread="0.50228"/>
                    <measurement group_id="O4" value="1.3915" spread="0.72178"/>
                    <measurement group_id="O5" value="1.2835" spread="0.41700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8503" spread="0.36457"/>
                    <measurement group_id="O2" value="0.6670" spread="0.16724"/>
                    <measurement group_id="O3" value="0.7900" spread="0.20432"/>
                    <measurement group_id="O4" value="0.9588" spread="0.53966"/>
                    <measurement group_id="O5" value="0.7246" spread="0.24992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7726" spread="0.35421"/>
                    <measurement group_id="O2" value="0.6564" spread="0.20882"/>
                    <measurement group_id="O3" value="0.5936" spread="0.24072"/>
                    <measurement group_id="O4" value="0.8479" spread="0.54882"/>
                    <measurement group_id="O5" value="0.6957" spread="0.22589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8554" spread="0.32384"/>
                    <measurement group_id="O2" value="0.6238" spread="0.16501"/>
                    <measurement group_id="O3" value="0.7308" spread="0.23372"/>
                    <measurement group_id="O4" value="0.8852" spread="0.33731"/>
                    <measurement group_id="O5" value="0.6712" spread="0.29185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1119" spread="0.50819"/>
                    <measurement group_id="O2" value="0.9531" spread="0.45374"/>
                    <measurement group_id="O3" value="0.9030" spread="0.45314"/>
                    <measurement group_id="O4" value="1.1811" spread="0.42979"/>
                    <measurement group_id="O5" value="0.7591" spread="0.23030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1607" spread="2.78517"/>
                    <measurement group_id="O2" value="7.0729" spread="2.28843"/>
                    <measurement group_id="O3" value="9.0225" spread="3.17595"/>
                    <measurement group_id="O4" value="9.4199" spread="2.80762"/>
                    <measurement group_id="O5" value="8.2319" spread="2.78227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3494" spread="2.81972"/>
                    <measurement group_id="O2" value="6.8724" spread="2.39872"/>
                    <measurement group_id="O3" value="8.6555" spread="4.16819"/>
                    <measurement group_id="O4" value="8.3912" spread="3.64530"/>
                    <measurement group_id="O5" value="8.1779" spread="2.36852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0317" spread="2.21593"/>
                    <measurement group_id="O2" value="5.4550" spread="2.01330"/>
                    <measurement group_id="O3" value="7.7675" spread="2.93749"/>
                    <measurement group_id="O4" value="8.4700" spread="3.48850"/>
                    <measurement group_id="O5" value="6.9604" spread="3.51501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7596" spread="3.53180"/>
                    <measurement group_id="O2" value="7.8463" spread="3.49800"/>
                    <measurement group_id="O3" value="9.4750" spread="3.26687"/>
                    <measurement group_id="O4" value="9.7576" spread="4.00884"/>
                    <measurement group_id="O5" value="8.4943" spread="4.71139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" spread="46.84"/>
                    <measurement group_id="O2" value="109.6" spread="36.21"/>
                    <measurement group_id="O3" value="152.0" spread="60.65"/>
                    <measurement group_id="O4" value="145.2" spread="52.96"/>
                    <measurement group_id="O5" value="149.5" spread="45.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.1" spread="54.62"/>
                    <measurement group_id="O2" value="124.5" spread="39.16"/>
                    <measurement group_id="O3" value="152.4" spread="66.02"/>
                    <measurement group_id="O4" value="144.6" spread="44.73"/>
                    <measurement group_id="O5" value="144.1" spread="39.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.0" spread="58.25"/>
                    <measurement group_id="O2" value="138.9" spread="28.15"/>
                    <measurement group_id="O3" value="177.3" spread="68.96"/>
                    <measurement group_id="O4" value="183.1" spread="53.62"/>
                    <measurement group_id="O5" value="176.1" spread="44.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.1" spread="87.28"/>
                    <measurement group_id="O2" value="262.4" spread="76.44"/>
                    <measurement group_id="O3" value="253.6" spread="84.79"/>
                    <measurement group_id="O4" value="284.0" spread="84.37"/>
                    <measurement group_id="O5" value="300.6" spread="105.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.17" spread="3.394"/>
                    <measurement group_id="O2" value="8.80" spread="2.480"/>
                    <measurement group_id="O3" value="10.95" spread="3.028"/>
                    <measurement group_id="O4" value="11.67" spread="3.377"/>
                    <measurement group_id="O5" value="10.88" spread="3.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.43" spread="3.482"/>
                    <measurement group_id="O2" value="8.55" spread="2.206"/>
                    <measurement group_id="O3" value="10.38" spread="4.105"/>
                    <measurement group_id="O4" value="10.47" spread="4.112"/>
                    <measurement group_id="O5" value="10.36" spread="2.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.26" spread="2.544"/>
                    <measurement group_id="O2" value="7.26" spread="1.859"/>
                    <measurement group_id="O3" value="9.68" spread="2.954"/>
                    <measurement group_id="O4" value="10.72" spread="3.694"/>
                    <measurement group_id="O5" value="9.78" spread="3.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="3.894"/>
                    <measurement group_id="O2" value="10.73" spread="3.973"/>
                    <measurement group_id="O3" value="11.34" spread="3.312"/>
                    <measurement group_id="O4" value="13.60" spread="5.614"/>
                    <measurement group_id="O5" value="11.18" spread="5.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Hematology Parameters- Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)</title>
        <description>Mean hematology parameters including hemoglobin, MCHC were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hematology Parameters- Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)</title>
          <description>Mean hematology parameters including hemoglobin, MCHC were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.8" spread="17.05"/>
                    <measurement group_id="O2" value="97.0" spread="16.27"/>
                    <measurement group_id="O3" value="97.8" spread="22.04"/>
                    <measurement group_id="O4" value="88.4" spread="12.46"/>
                    <measurement group_id="O5" value="97.2" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" spread="15.27"/>
                    <measurement group_id="O2" value="96.0" spread="17.48"/>
                    <measurement group_id="O3" value="93.7" spread="19.40"/>
                    <measurement group_id="O4" value="82.9" spread="9.29"/>
                    <measurement group_id="O5" value="95.2" spread="20.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" spread="12.94"/>
                    <measurement group_id="O2" value="96.5" spread="16.50"/>
                    <measurement group_id="O3" value="93.0" spread="15.36"/>
                    <measurement group_id="O4" value="84.7" spread="9.73"/>
                    <measurement group_id="O5" value="95.1" spread="19.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin: follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="14.97"/>
                    <measurement group_id="O2" value="103.5" spread="16.42"/>
                    <measurement group_id="O3" value="99.6" spread="15.49"/>
                    <measurement group_id="O4" value="88.8" spread="8.93"/>
                    <measurement group_id="O5" value="99.2" spread="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC :Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.2" spread="10.96"/>
                    <measurement group_id="O2" value="343.8" spread="4.17"/>
                    <measurement group_id="O3" value="339.3" spread="6.96"/>
                    <measurement group_id="O4" value="339.1" spread="9.43"/>
                    <measurement group_id="O5" value="343.6" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.4" spread="9.30"/>
                    <measurement group_id="O2" value="343.1" spread="8.15"/>
                    <measurement group_id="O3" value="338.7" spread="7.64"/>
                    <measurement group_id="O4" value="339.1" spread="7.43"/>
                    <measurement group_id="O5" value="341.2" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.2" spread="9.33"/>
                    <measurement group_id="O2" value="342.9" spread="6.90"/>
                    <measurement group_id="O3" value="338.1" spread="9.34"/>
                    <measurement group_id="O4" value="336.4" spread="10.03"/>
                    <measurement group_id="O5" value="342.8" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.4" spread="12.09"/>
                    <measurement group_id="O2" value="339.5" spread="10.74"/>
                    <measurement group_id="O3" value="337.8" spread="9.72"/>
                    <measurement group_id="O4" value="331.1" spread="11.89"/>
                    <measurement group_id="O5" value="342.5" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Hematology Parameters- Mean Corpuscle Hemoglobin</title>
        <description>Hematology parameter mean corpuscle hemoglobin was reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hematology Parameters- Mean Corpuscle Hemoglobin</title>
          <description>Hematology parameter mean corpuscle hemoglobin was reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Picogram (pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Corpuscle Hemoglobin: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.46" spread="1.340"/>
                    <measurement group_id="O2" value="30.74" spread="1.241"/>
                    <measurement group_id="O3" value="30.11" spread="1.262"/>
                    <measurement group_id="O4" value="30.18" spread="1.997"/>
                    <measurement group_id="O5" value="31.10" spread="1.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.21" spread="1.319"/>
                    <measurement group_id="O2" value="30.78" spread="1.290"/>
                    <measurement group_id="O3" value="30.22" spread="1.135"/>
                    <measurement group_id="O4" value="30.19" spread="1.771"/>
                    <measurement group_id="O5" value="30.77" spread="1.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.25" spread="1.359"/>
                    <measurement group_id="O2" value="30.80" spread="1.153"/>
                    <measurement group_id="O3" value="30.33" spread="1.378"/>
                    <measurement group_id="O4" value="30.06" spread="1.808"/>
                    <measurement group_id="O5" value="30.92" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin:Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.02" spread="1.141"/>
                    <measurement group_id="O2" value="30.64" spread="1.308"/>
                    <measurement group_id="O3" value="30.13" spread="1.234"/>
                    <measurement group_id="O4" value="29.82" spread="1.768"/>
                    <measurement group_id="O5" value="31.08" spread="1.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology Parameters-Mean Corpuscle Volume</title>
        <description>Absolute values of mean corpuscle volume were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology Parameters-Mean Corpuscle Volume</title>
          <description>Absolute values of mean corpuscle volume were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Corpuscle Volume:Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.30" spread="4.024"/>
                    <measurement group_id="O2" value="89.59" spread="3.379"/>
                    <measurement group_id="O3" value="88.33" spread="3.367"/>
                    <measurement group_id="O4" value="89.15" spread="4.828"/>
                    <measurement group_id="O5" value="90.63" spread="2.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.85" spread="3.833"/>
                    <measurement group_id="O2" value="89.70" spread="2.804"/>
                    <measurement group_id="O3" value="89.00" spread="3.742"/>
                    <measurement group_id="O4" value="89.18" spread="4.375"/>
                    <measurement group_id="O5" value="90.48" spread="3.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.41" spread="3.920"/>
                    <measurement group_id="O2" value="89.96" spread="2.295"/>
                    <measurement group_id="O3" value="89.50" spread="3.920"/>
                    <measurement group_id="O4" value="89.45" spread="4.285"/>
                    <measurement group_id="O5" value="90.08" spread="2.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.12" spread="3.430"/>
                    <measurement group_id="O2" value="89.86" spread="2.738"/>
                    <measurement group_id="O3" value="89.67" spread="3.869"/>
                    <measurement group_id="O4" value="90.43" spread="4.079"/>
                    <measurement group_id="O5" value="90.75" spread="3.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Hematology Parameters-reticulocytes, Red Blood Cell Count</title>
        <description>Absolute values of reticulocytes and red blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hematology Parameters-reticulocytes, Red Blood Cell Count</title>
          <description>Absolute values of reticulocytes and red blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Trillion cells per liter (TI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reticulocytes : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0488" spread="0.01974"/>
                    <measurement group_id="O2" value="0.0411" spread="0.01902"/>
                    <measurement group_id="O3" value="0.0406" spread="0.00863"/>
                    <measurement group_id="O4" value="0.0398" spread="0.01218"/>
                    <measurement group_id="O5" value="0.0513" spread="0.02192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0554" spread="0.01871"/>
                    <measurement group_id="O2" value="0.0448" spread="0.01903"/>
                    <measurement group_id="O3" value="0.0464" spread="0.01284"/>
                    <measurement group_id="O4" value="0.0474" spread="0.01382"/>
                    <measurement group_id="O5" value="0.0576" spread="0.02543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0662" spread="0.02171"/>
                    <measurement group_id="O2" value="0.0592" spread="0.02654"/>
                    <measurement group_id="O3" value="0.0538" spread="0.01876"/>
                    <measurement group_id="O4" value="0.0581" spread="0.01748"/>
                    <measurement group_id="O5" value="0.0699" spread="0.02818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0934" spread="0.04509"/>
                    <measurement group_id="O2" value="0.0979" spread="0.04134"/>
                    <measurement group_id="O3" value="0.0829" spread="0.05170"/>
                    <measurement group_id="O4" value="0.0897" spread="0.03964"/>
                    <measurement group_id="O5" value="0.1213" spread="0.06734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.320" spread="0.6164"/>
                    <measurement group_id="O2" value="3.151" spread="0.4434"/>
                    <measurement group_id="O3" value="3.253" spread="0.6883"/>
                    <measurement group_id="O4" value="2.943" spread="0.4695"/>
                    <measurement group_id="O5" value="3.121" spread="0.6197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.007" spread="0.5787"/>
                    <measurement group_id="O2" value="3.110" spread="0.5001"/>
                    <measurement group_id="O3" value="3.103" spread="0.6117"/>
                    <measurement group_id="O4" value="2.758" spread="0.3615"/>
                    <measurement group_id="O5" value="3.083" spread="0.6114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.054" spread="0.5220"/>
                    <measurement group_id="O2" value="3.128" spread="0.4706"/>
                    <measurement group_id="O3" value="3.071" spread="0.5146"/>
                    <measurement group_id="O4" value="2.822" spread="0.3372"/>
                    <measurement group_id="O5" value="3.062" spread="0.5799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.144" spread="0.5268"/>
                    <measurement group_id="O2" value="3.379" spread="0.4695"/>
                    <measurement group_id="O3" value="3.313" spread="0.5365"/>
                    <measurement group_id="O4" value="2.983" spread="0.3445"/>
                    <measurement group_id="O5" value="3.183" spread="0.4403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Clinical Chemistry Parameters- Albumin and Total Protein</title>
        <description>Absolute values of albumin and total protein were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Chemistry Parameters- Albumin and Total Protein</title>
          <description>Absolute values of albumin and total protein were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="4.27"/>
                    <measurement group_id="O2" value="25.1" spread="5.72"/>
                    <measurement group_id="O3" value="23.7" spread="3.69"/>
                    <measurement group_id="O4" value="26.2" spread="3.45"/>
                    <measurement group_id="O5" value="24.7" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="4.29"/>
                    <measurement group_id="O2" value="25.6" spread="4.96"/>
                    <measurement group_id="O3" value="22.6" spread="5.45"/>
                    <measurement group_id="O4" value="23.1" spread="3.51"/>
                    <measurement group_id="O5" value="25.1" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="3.99"/>
                    <measurement group_id="O2" value="24.1" spread="4.56"/>
                    <measurement group_id="O3" value="22.7" spread="4.85"/>
                    <measurement group_id="O4" value="22.6" spread="3.90"/>
                    <measurement group_id="O5" value="24.3" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="6.34"/>
                    <measurement group_id="O2" value="25.5" spread="4.87"/>
                    <measurement group_id="O3" value="21.6" spread="4.74"/>
                    <measurement group_id="O4" value="22.0" spread="3.86"/>
                    <measurement group_id="O5" value="26.8" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="7.39"/>
                    <measurement group_id="O2" value="47.1" spread="9.44"/>
                    <measurement group_id="O3" value="46.8" spread="7.64"/>
                    <measurement group_id="O4" value="48.9" spread="5.76"/>
                    <measurement group_id="O5" value="51.1" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="8.01"/>
                    <measurement group_id="O2" value="50.0" spread="7.02"/>
                    <measurement group_id="O3" value="46.3" spread="9.24"/>
                    <measurement group_id="O4" value="47.1" spread="3.82"/>
                    <measurement group_id="O5" value="52.7" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="7.09"/>
                    <measurement group_id="O2" value="49.6" spread="3.82"/>
                    <measurement group_id="O3" value="49.2" spread="7.78"/>
                    <measurement group_id="O4" value="49.0" spread="5.00"/>
                    <measurement group_id="O5" value="53.2" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="9.54"/>
                    <measurement group_id="O2" value="55.6" spread="4.27"/>
                    <measurement group_id="O3" value="50.3" spread="8.66"/>
                    <measurement group_id="O4" value="52.3" spread="7.41"/>
                    <measurement group_id="O5" value="58.5" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Clinical Chemistry Parameters-alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase and Gamma Glutamyl Transferase</title>
        <description>Absolute values of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and gamma glutamyl transferase were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Chemistry Parameters-alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase and Gamma Glutamyl Transferase</title>
          <description>Absolute values of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and gamma glutamyl transferase were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="19.99"/>
                    <measurement group_id="O2" value="53.8" spread="12.53"/>
                    <measurement group_id="O3" value="43.5" spread="8.19"/>
                    <measurement group_id="O4" value="49.4" spread="21.15"/>
                    <measurement group_id="O5" value="52.2" spread="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="20.35"/>
                    <measurement group_id="O2" value="73.1" spread="45.57"/>
                    <measurement group_id="O3" value="48.6" spread="11.07"/>
                    <measurement group_id="O4" value="50.8" spread="26.85"/>
                    <measurement group_id="O5" value="55.6" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="37.08"/>
                    <measurement group_id="O2" value="76.0" spread="44.67"/>
                    <measurement group_id="O3" value="53.5" spread="13.19"/>
                    <measurement group_id="O4" value="60.6" spread="34.38"/>
                    <measurement group_id="O5" value="59.5" spread="25.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="57.58"/>
                    <measurement group_id="O2" value="118.1" spread="58.77"/>
                    <measurement group_id="O3" value="69.8" spread="39.40"/>
                    <measurement group_id="O4" value="94.5" spread="59.93"/>
                    <measurement group_id="O5" value="90.0" spread="60.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="26.48"/>
                    <measurement group_id="O2" value="37.8" spread="26.63"/>
                    <measurement group_id="O3" value="60.5" spread="37.89"/>
                    <measurement group_id="O4" value="45.4" spread="22.67"/>
                    <measurement group_id="O5" value="53.8" spread="49.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" spread="18.64"/>
                    <measurement group_id="O2" value="43.4" spread="48.84"/>
                    <measurement group_id="O3" value="50.8" spread="26.93"/>
                    <measurement group_id="O4" value="37.5" spread="15.91"/>
                    <measurement group_id="O5" value="41.4" spread="32.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="21.93"/>
                    <measurement group_id="O2" value="53.3" spread="62.19"/>
                    <measurement group_id="O3" value="49.1" spread="21.82"/>
                    <measurement group_id="O4" value="34.3" spread="15.14"/>
                    <measurement group_id="O5" value="42.3" spread="29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="50.95"/>
                    <measurement group_id="O2" value="77.4" spread="58.39"/>
                    <measurement group_id="O3" value="117.8" spread="158.33"/>
                    <measurement group_id="O4" value="42.2" spread="21.73"/>
                    <measurement group_id="O5" value="59.1" spread="52.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="42.35"/>
                    <measurement group_id="O2" value="57.1" spread="28.41"/>
                    <measurement group_id="O3" value="125.2" spread="65.22"/>
                    <measurement group_id="O4" value="83.2" spread="40.61"/>
                    <measurement group_id="O5" value="81.4" spread="53.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="62.80"/>
                    <measurement group_id="O2" value="64.9" spread="58.77"/>
                    <measurement group_id="O3" value="90.5" spread="44.66"/>
                    <measurement group_id="O4" value="65.8" spread="31.23"/>
                    <measurement group_id="O5" value="62.3" spread="29.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="93.43"/>
                    <measurement group_id="O2" value="81.3" spread="79.91"/>
                    <measurement group_id="O3" value="84.9" spread="37.84"/>
                    <measurement group_id="O4" value="53.1" spread="29.14"/>
                    <measurement group_id="O5" value="71.9" spread="66.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="46.83"/>
                    <measurement group_id="O2" value="64.9" spread="31.73"/>
                    <measurement group_id="O3" value="137.1" spread="192.21"/>
                    <measurement group_id="O4" value="48.3" spread="21.76"/>
                    <measurement group_id="O5" value="65.6" spread="59.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3287.8" spread="3333.83"/>
                    <measurement group_id="O2" value="1174.0" spread="996.71"/>
                    <measurement group_id="O3" value="4663.1" spread="4797.79"/>
                    <measurement group_id="O4" value="2797.2" spread="2022.44"/>
                    <measurement group_id="O5" value="2527.8" spread="2507.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2668.0" spread="4149.97"/>
                    <measurement group_id="O2" value="1183.8" spread="944.80"/>
                    <measurement group_id="O3" value="4418.9" spread="5201.64"/>
                    <measurement group_id="O4" value="2307.0" spread="1670.81"/>
                    <measurement group_id="O5" value="2418.9" spread="3267.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2527.4" spread="5594.82"/>
                    <measurement group_id="O2" value="1638.3" spread="2178.26"/>
                    <measurement group_id="O3" value="3342.3" spread="2222.65"/>
                    <measurement group_id="O4" value="1410.2" spread="1417.50"/>
                    <measurement group_id="O5" value="1227.8" spread="1038.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954.3" spread="2023.51"/>
                    <measurement group_id="O2" value="503.8" spread="725.49"/>
                    <measurement group_id="O3" value="1349.9" spread="1296.97"/>
                    <measurement group_id="O4" value="602.1" spread="476.66"/>
                    <measurement group_id="O5" value="366.4" spread="329.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="20.05"/>
                    <measurement group_id="O2" value="20.8" spread="8.80"/>
                    <measurement group_id="O3" value="34.0" spread="46.54"/>
                    <measurement group_id="O4" value="26.3" spread="23.01"/>
                    <measurement group_id="O5" value="17.3" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="23.02"/>
                    <measurement group_id="O2" value="23.0" spread="9.81"/>
                    <measurement group_id="O3" value="25.4" spread="15.36"/>
                    <measurement group_id="O4" value="23.7" spread="18.42"/>
                    <measurement group_id="O5" value="26.9" spread="31.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="47.61"/>
                    <measurement group_id="O2" value="31.3" spread="22.68"/>
                    <measurement group_id="O3" value="38.4" spread="33.91"/>
                    <measurement group_id="O4" value="43.4" spread="46.70"/>
                    <measurement group_id="O5" value="39.3" spread="54.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="61.62"/>
                    <measurement group_id="O2" value="70.6" spread="49.58"/>
                    <measurement group_id="O3" value="48.3" spread="41.93"/>
                    <measurement group_id="O4" value="86.7" spread="90.58"/>
                    <measurement group_id="O5" value="45.6" spread="46.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Clinical Chemistry Parameters- Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid</title>
        <description>Absolute values of direct bilirubin, total bilirubin, creatinine and uric acid were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Chemistry Parameters- Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid</title>
          <description>Absolute values of direct bilirubin, total bilirubin, creatinine and uric acid were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Micromol per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.500" spread="1.6333"/>
                    <measurement group_id="O2" value="4.275" spread="2.0438"/>
                    <measurement group_id="O3" value="8.705" spread="11.6846"/>
                    <measurement group_id="O4" value="5.985" spread="6.9250"/>
                    <measurement group_id="O5" value="3.306" spread="1.6436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.590" spread="1.9789"/>
                    <measurement group_id="O2" value="4.275" spread="1.5832"/>
                    <measurement group_id="O3" value="6.995" spread="7.2329"/>
                    <measurement group_id="O4" value="6.840" spread="9.5974"/>
                    <measurement group_id="O5" value="3.420" spread="2.2076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.890" spread="4.0305"/>
                    <measurement group_id="O2" value="4.703" spread="2.5446"/>
                    <measurement group_id="O3" value="7.773" spread="10.6340"/>
                    <measurement group_id="O4" value="6.639" spread="9.7463"/>
                    <measurement group_id="O5" value="4.998" spread="4.1572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.110" spread="5.7923"/>
                    <measurement group_id="O2" value="7.695" spread="8.7671"/>
                    <measurement group_id="O3" value="26.030" spread="58.4146"/>
                    <measurement group_id="O4" value="10.964" spread="22.2140"/>
                    <measurement group_id="O5" value="9.120" spread="16.4864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.238" spread="9.9071"/>
                    <measurement group_id="O2" value="17.314" spread="8.7403"/>
                    <measurement group_id="O3" value="24.717" spread="16.4971"/>
                    <measurement group_id="O4" value="15.675" spread="8.8223"/>
                    <measurement group_id="O5" value="18.145" spread="14.8048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.126" spread="6.1128"/>
                    <measurement group_id="O2" value="16.245" spread="5.9937"/>
                    <measurement group_id="O3" value="20.520" spread="14.7497"/>
                    <measurement group_id="O4" value="18.408" spread="11.8245"/>
                    <measurement group_id="O5" value="15.604" spread="6.7214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.430" spread="7.6574"/>
                    <measurement group_id="O2" value="19.238" spread="8.1112"/>
                    <measurement group_id="O3" value="21.608" spread="15.0494"/>
                    <measurement group_id="O4" value="19.615" spread="12.2882"/>
                    <measurement group_id="O5" value="18.596" spread="9.6505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.880" spread="8.4271"/>
                    <measurement group_id="O2" value="24.581" spread="15.2383"/>
                    <measurement group_id="O3" value="53.390" spread="98.8728"/>
                    <measurement group_id="O4" value="26.656" spread="30.4820"/>
                    <measurement group_id="O5" value="22.978" spread="22.7112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6428" spread="23.25282"/>
                    <measurement group_id="O2" value="83.4275" spread="49.48807"/>
                    <measurement group_id="O3" value="87.9982" spread="34.95181"/>
                    <measurement group_id="O4" value="90.9538" spread="66.75768"/>
                    <measurement group_id="O5" value="80.1984" spread="32.87944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1620" spread="22.69678"/>
                    <measurement group_id="O2" value="80.2230" spread="51.77845"/>
                    <measurement group_id="O3" value="87.9178" spread="53.40174"/>
                    <measurement group_id="O4" value="87.4640" spread="65.10727"/>
                    <measurement group_id="O5" value="72.9560" spread="31.73042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9756" spread="22.20243"/>
                    <measurement group_id="O2" value="73.0405" spread="45.07022"/>
                    <measurement group_id="O3" value="89.7260" spread="84.44314"/>
                    <measurement group_id="O4" value="90.8960" spread="91.11701"/>
                    <measurement group_id="O5" value="78.1788" spread="28.17353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7200" spread="25.41831"/>
                    <measurement group_id="O2" value="71.8250" spread="31.43842"/>
                    <measurement group_id="O3" value="85.9690" spread="61.38913"/>
                    <measurement group_id="O4" value="98.7480" spread="110.4008"/>
                    <measurement group_id="O5" value="76.9080" spread="35.07431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.7450" spread="79.77454"/>
                    <measurement group_id="O2" value="207.4365" spread="76.26689"/>
                    <measurement group_id="O3" value="194.1211" spread="99.68084"/>
                    <measurement group_id="O4" value="246.5116" spread="96.00019"/>
                    <measurement group_id="O5" value="231.9720" spread="76.04761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.2802" spread="76.68988"/>
                    <measurement group_id="O2" value="202.9755" spread="83.29855"/>
                    <measurement group_id="O3" value="202.7727" spread="83.20631"/>
                    <measurement group_id="O4" value="233.3715" spread="101.8900"/>
                    <measurement group_id="O5" value="226.4205" spread="79.05205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.6491" spread="75.69201"/>
                    <measurement group_id="O2" value="194.0535" spread="90.48210"/>
                    <measurement group_id="O3" value="192.4989" spread="95.58615"/>
                    <measurement group_id="O4" value="222.8751" spread="115.7210"/>
                    <measurement group_id="O5" value="247.0403" spread="87.73096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.4747" spread="74.95979"/>
                    <measurement group_id="O2" value="171.0050" spread="62.36289"/>
                    <measurement group_id="O3" value="188.8490" spread="106.1990"/>
                    <measurement group_id="O4" value="221.4755" spread="129.6427"/>
                    <measurement group_id="O5" value="253.7813" spread="118.3352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Clinical Chemistry Parameters- Calcium, Chloride, Glucose, Bicarbonate, Potassium, Sodium and Ratio of Urea to Blood Urea Nitrogen (Urea/BUN)</title>
        <description>Absolute values of calcium, chloride, glucose, bicarbonate, potassium, sodium and Urea/BUN were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>“Day 2, pre-dose&quot;, &quot;Day 3, pre-dose&quot;, &quot;Day 3, 24 h&quot; and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Chemistry Parameters- Calcium, Chloride, Glucose, Bicarbonate, Potassium, Sodium and Ratio of Urea to Blood Urea Nitrogen (Urea/BUN)</title>
          <description>Absolute values of calcium, chloride, glucose, bicarbonate, potassium, sodium and Urea/BUN were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Millimole per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9523" spread="0.11501"/>
                    <measurement group_id="O2" value="1.9274" spread="0.12913"/>
                    <measurement group_id="O3" value="1.9098" spread="0.11828"/>
                    <measurement group_id="O4" value="1.9489" spread="0.08889"/>
                    <measurement group_id="O5" value="1.9655" spread="0.13867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9523" spread="0.10857"/>
                    <measurement group_id="O2" value="1.9835" spread="0.11158"/>
                    <measurement group_id="O3" value="1.9007" spread="0.08411"/>
                    <measurement group_id="O4" value="1.9314" spread="0.12383"/>
                    <measurement group_id="O5" value="1.9887" spread="0.15273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9881" spread="0.09701"/>
                    <measurement group_id="O2" value="2.0272" spread="0.09312"/>
                    <measurement group_id="O3" value="1.9565" spread="0.15138"/>
                    <measurement group_id="O4" value="1.9432" spread="0.09120"/>
                    <measurement group_id="O5" value="2.0116" spread="0.15132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0617" spread="0.14021"/>
                    <measurement group_id="O2" value="2.0989" spread="0.12612"/>
                    <measurement group_id="O3" value="2.0005" spread="0.15773"/>
                    <measurement group_id="O4" value="2.0386" spread="0.11794"/>
                    <measurement group_id="O5" value="2.0958" spread="0.14441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.5" spread="5.04"/>
                    <measurement group_id="O2" value="105.5" spread="4.69"/>
                    <measurement group_id="O3" value="107.5" spread="3.62"/>
                    <measurement group_id="O4" value="106.3" spread="4.17"/>
                    <measurement group_id="O5" value="105.3" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.3" spread="5.66"/>
                    <measurement group_id="O2" value="105.5" spread="4.93"/>
                    <measurement group_id="O3" value="107.7" spread="4.67"/>
                    <measurement group_id="O4" value="105.9" spread="5.89"/>
                    <measurement group_id="O5" value="105.7" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.6" spread="5.12"/>
                    <measurement group_id="O2" value="104.4" spread="4.98"/>
                    <measurement group_id="O3" value="106.0" spread="5.54"/>
                    <measurement group_id="O4" value="106.4" spread="5.84"/>
                    <measurement group_id="O5" value="105.3" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.2" spread="7.84"/>
                    <measurement group_id="O2" value="101.8" spread="4.59"/>
                    <measurement group_id="O3" value="106.2" spread="5.13"/>
                    <measurement group_id="O4" value="104.5" spread="6.07"/>
                    <measurement group_id="O5" value="102.2" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8028" spread="2.22918"/>
                    <measurement group_id="O2" value="8.0628" spread="1.92721"/>
                    <measurement group_id="O3" value="6.9690" spread="1.03682"/>
                    <measurement group_id="O4" value="7.8763" spread="2.30585"/>
                    <measurement group_id="O5" value="7.3797" spread="4.08342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7889" spread="1.93504"/>
                    <measurement group_id="O2" value="7.2094" spread="1.67306"/>
                    <measurement group_id="O3" value="6.2878" spread="1.22124"/>
                    <measurement group_id="O4" value="7.8530" spread="2.96473"/>
                    <measurement group_id="O5" value="6.2530" spread="0.98343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6575" spread="4.44567"/>
                    <measurement group_id="O2" value="6.2865" spread="1.01307"/>
                    <measurement group_id="O3" value="6.1662" spread="0.84863"/>
                    <measurement group_id="O4" value="7.7192" spread="3.27506"/>
                    <measurement group_id="O5" value="6.0321" spread="1.32273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6115" spread="1.95391"/>
                    <measurement group_id="O2" value="6.3698" spread="0.55172"/>
                    <measurement group_id="O3" value="6.4139" spread="1.50295"/>
                    <measurement group_id="O4" value="6.9110" spread="2.14454"/>
                    <measurement group_id="O5" value="6.2563" spread="1.41547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="2.73"/>
                    <measurement group_id="O2" value="25.9" spread="2.36"/>
                    <measurement group_id="O3" value="25.6" spread="2.11"/>
                    <measurement group_id="O4" value="25.9" spread="2.55"/>
                    <measurement group_id="O5" value="25.6" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="1.96"/>
                    <measurement group_id="O2" value="27.8" spread="2.92"/>
                    <measurement group_id="O3" value="26.5" spread="2.91"/>
                    <measurement group_id="O4" value="26.5" spread="3.47"/>
                    <measurement group_id="O5" value="25.7" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="2.70"/>
                    <measurement group_id="O2" value="28.5" spread="2.62"/>
                    <measurement group_id="O3" value="27.3" spread="3.86"/>
                    <measurement group_id="O4" value="26.6" spread="2.18"/>
                    <measurement group_id="O5" value="25.3" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="2.75"/>
                    <measurement group_id="O2" value="27.3" spread="2.49"/>
                    <measurement group_id="O3" value="28.3" spread="1.91"/>
                    <measurement group_id="O4" value="27.1" spread="2.67"/>
                    <measurement group_id="O5" value="26.7" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="0.558"/>
                    <measurement group_id="O2" value="3.89" spread="0.348"/>
                    <measurement group_id="O3" value="4.17" spread="0.374"/>
                    <measurement group_id="O4" value="4.10" spread="0.468"/>
                    <measurement group_id="O5" value="4.12" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="0.318"/>
                    <measurement group_id="O2" value="3.96" spread="0.267"/>
                    <measurement group_id="O3" value="4.15" spread="0.491"/>
                    <measurement group_id="O4" value="4.00" spread="0.550"/>
                    <measurement group_id="O5" value="3.99" spread="0.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="0.347"/>
                    <measurement group_id="O2" value="3.91" spread="0.280"/>
                    <measurement group_id="O3" value="3.93" spread="0.442"/>
                    <measurement group_id="O4" value="3.91" spread="0.496"/>
                    <measurement group_id="O5" value="3.95" spread="0.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="0.435"/>
                    <measurement group_id="O2" value="4.01" spread="0.473"/>
                    <measurement group_id="O3" value="3.70" spread="0.357"/>
                    <measurement group_id="O4" value="3.99" spread="0.405"/>
                    <measurement group_id="O5" value="3.98" spread="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.1" spread="3.61"/>
                    <measurement group_id="O2" value="136.3" spread="3.45"/>
                    <measurement group_id="O3" value="136.7" spread="3.44"/>
                    <measurement group_id="O4" value="136.7" spread="2.97"/>
                    <measurement group_id="O5" value="137.2" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.0" spread="3.91"/>
                    <measurement group_id="O2" value="138.4" spread="3.29"/>
                    <measurement group_id="O3" value="138.5" spread="3.80"/>
                    <measurement group_id="O4" value="137.6" spread="3.69"/>
                    <measurement group_id="O5" value="138.1" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" spread="4.15"/>
                    <measurement group_id="O2" value="137.9" spread="3.48"/>
                    <measurement group_id="O3" value="138.5" spread="3.09"/>
                    <measurement group_id="O4" value="138.4" spread="3.86"/>
                    <measurement group_id="O5" value="137.9" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.6" spread="5.96"/>
                    <measurement group_id="O2" value="137.1" spread="4.97"/>
                    <measurement group_id="O3" value="140.2" spread="5.22"/>
                    <measurement group_id="O4" value="139.0" spread="5.05"/>
                    <measurement group_id="O5" value="136.6" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN : Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7664" spread="2.13093"/>
                    <measurement group_id="O2" value="3.4361" spread="3.16986"/>
                    <measurement group_id="O3" value="4.3392" spread="3.00056"/>
                    <measurement group_id="O4" value="4.9385" spread="3.44877"/>
                    <measurement group_id="O5" value="4.6013" spread="2.85045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN : Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4808" spread="1.57061"/>
                    <measurement group_id="O2" value="3.7485" spread="3.85447"/>
                    <measurement group_id="O3" value="4.9655" spread="4.52265"/>
                    <measurement group_id="O4" value="4.8510" spread="3.92306"/>
                    <measurement group_id="O5" value="4.6200" spread="2.93162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN : Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1525" spread="2.34164"/>
                    <measurement group_id="O2" value="4.3286" spread="4.26883"/>
                    <measurement group_id="O3" value="4.9683" spread="6.06128"/>
                    <measurement group_id="O4" value="5.4390" spread="5.13095"/>
                    <measurement group_id="O5" value="4.8418" spread="2.59399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9938" spread="5.08449"/>
                    <measurement group_id="O2" value="6.0244" spread="4.20870"/>
                    <measurement group_id="O3" value="6.2313" spread="7.18868"/>
                    <measurement group_id="O4" value="7.1610" spread="8.27331"/>
                    <measurement group_id="O5" value="5.3340" spread="2.80100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Clinical Chemistry Parameters-estradiol</title>
        <description>Absolute values of Estradiol were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
        <time_frame>Day 1 (pre-dose) and Day 3 (24 h)</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed. Data were not collected from participants in Cohort 2-SB-681323, 7.5 mg, 24 h, Cohort 3-SB-681323, 7.5 mg, 4 h, and Cohort 4-SB-681323, 10 mg, 24 h.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Chemistry Parameters-estradiol</title>
          <description>Absolute values of Estradiol were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed. Data were not collected from participants in Cohort 2-SB-681323, 7.5 mg, 24 h, Cohort 3-SB-681323, 7.5 mg, 4 h, and Cohort 4-SB-681323, 10 mg, 24 h.</population>
          <units>Picomole per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.150">Only one participant was available at the time of analysis, dispersion could not be calculated.</measurement>
                    <measurement group_id="O2" value="210.108" spread="100.8360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Clinical Chemistry Parameters-Blood pH at Screening</title>
        <description>Absolute values of Blood pH at screening were reported as clinical chemistry parameter.</description>
        <time_frame>Screening</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Chemistry Parameters-Blood pH at Screening</title>
          <description>Absolute values of Blood pH at screening were reported as clinical chemistry parameter.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>pH Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.358" spread="0.0738"/>
                    <measurement group_id="O2" value="7.363" spread="0.0824"/>
                    <measurement group_id="O3" value="7.358" spread="0.0354"/>
                    <measurement group_id="O4" value="7.353" spread="0.0297"/>
                    <measurement group_id="O5" value="7.373" spread="0.0527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Parameter- Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Absolute values of SBP and DBP were reported.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h” and &quot;Follow up (Day 7)&quot;; for Cohort 2 and 4: “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”, and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Parameter- Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Absolute values of SBP and DBP were reported.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Millimeter of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP : Day 1, 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.9" spread="20.93"/>
                    <measurement group_id="O2" value="116.6" spread="17.33"/>
                    <measurement group_id="O4" value="130.4" spread="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP : Day 2, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.4" spread="19.91"/>
                    <measurement group_id="O2" value="114.8" spread="13.72"/>
                    <measurement group_id="O3" value="130.3" spread="23.72"/>
                    <measurement group_id="O4" value="130.9" spread="24.15"/>
                    <measurement group_id="O5" value="127.1" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP : Day 3, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.5" spread="22.65"/>
                    <measurement group_id="O2" value="119.8" spread="16.65"/>
                    <measurement group_id="O3" value="140.4" spread="35.28"/>
                    <measurement group_id="O4" value="127.9" spread="21.43"/>
                    <measurement group_id="O5" value="136.0" spread="23.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP : Day 3, Pre-dose 24 H</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.7" spread="22.18"/>
                    <measurement group_id="O2" value="136.0" spread="23.66"/>
                    <measurement group_id="O3" value="130.3" spread="22.80"/>
                    <measurement group_id="O4" value="129.5" spread="20.23"/>
                    <measurement group_id="O5" value="128.6" spread="15.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.4" spread="19.50"/>
                    <measurement group_id="O2" value="125.5" spread="14.06"/>
                    <measurement group_id="O3" value="134.3" spread="14.10"/>
                    <measurement group_id="O4" value="132.6" spread="27.34"/>
                    <measurement group_id="O5" value="137.9" spread="18.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP : Day 1, 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="11.57"/>
                    <measurement group_id="O2" value="61.8" spread="19.44"/>
                    <measurement group_id="O4" value="67.6" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP : Day 2, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="10.38"/>
                    <measurement group_id="O2" value="63.8" spread="11.57"/>
                    <measurement group_id="O3" value="58.9" spread="8.68"/>
                    <measurement group_id="O4" value="65.0" spread="12.28"/>
                    <measurement group_id="O5" value="61.7" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP : Day 3, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="12.04"/>
                    <measurement group_id="O2" value="63.4" spread="11.26"/>
                    <measurement group_id="O3" value="65.3" spread="13.45"/>
                    <measurement group_id="O4" value="64.6" spread="13.70"/>
                    <measurement group_id="O5" value="71.2" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP : Day 3, Pre-dose 24 H</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" spread="11.10"/>
                    <measurement group_id="O2" value="68.9" spread="10.99"/>
                    <measurement group_id="O3" value="68.9" spread="12.48"/>
                    <measurement group_id="O4" value="66.2" spread="11.09"/>
                    <measurement group_id="O5" value="74.5" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP : Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="12.42"/>
                    <measurement group_id="O2" value="67.9" spread="12.23"/>
                    <measurement group_id="O3" value="71.0" spread="9.82"/>
                    <measurement group_id="O4" value="69.3" spread="13.31"/>
                    <measurement group_id="O5" value="74.0" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Parameter: Mean Heart Rate</title>
        <description>Absolute values of mean heart rate were reported.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h” and &quot;Follow up (Day 7)&quot;; for Cohort 2 and 4: “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”, and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Parameter: Mean Heart Rate</title>
          <description>Absolute values of mean heart rate were reported.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate: Day 1, 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" spread="12.18"/>
                    <measurement group_id="O2" value="89.7" spread="17.63"/>
                    <measurement group_id="O4" value="97.8" spread="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" spread="16.92"/>
                    <measurement group_id="O2" value="93.8" spread="13.35"/>
                    <measurement group_id="O3" value="98.1" spread="27.01"/>
                    <measurement group_id="O4" value="97.1" spread="19.36"/>
                    <measurement group_id="O5" value="82.7" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" spread="15.13"/>
                    <measurement group_id="O2" value="99.3" spread="19.90"/>
                    <measurement group_id="O3" value="88.7" spread="24.73"/>
                    <measurement group_id="O4" value="93.8" spread="12.20"/>
                    <measurement group_id="O5" value="88.3" spread="17.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.4" spread="15.20"/>
                    <measurement group_id="O2" value="99.3" spread="12.69"/>
                    <measurement group_id="O3" value="93.7" spread="16.37"/>
                    <measurement group_id="O4" value="96.4" spread="15.74"/>
                    <measurement group_id="O5" value="90.5" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="13.42"/>
                    <measurement group_id="O2" value="93.3" spread="19.91"/>
                    <measurement group_id="O3" value="100.3" spread="18.79"/>
                    <measurement group_id="O4" value="96.8" spread="16.40"/>
                    <measurement group_id="O5" value="87.7" spread="14.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Sign: Mean Percent Oxygen (O2) in Blood</title>
        <description>Absolute values of mean percent O2 in blood were reported.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h” and &quot;Follow up (Day 7)&quot;; for Cohort 2 and 4: “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”, and &quot;Follow up (Day 7)&quot;</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Sign: Mean Percent Oxygen (O2) in Blood</title>
          <description>Absolute values of mean percent O2 in blood were reported.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percent O2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent O2 in blood: Day 1, 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="2.30"/>
                    <measurement group_id="O2" value="97.1" spread="2.98"/>
                    <measurement group_id="O4" value="97.6" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent O2 in blood: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="2.44"/>
                    <measurement group_id="O2" value="97.3" spread="2.05"/>
                    <measurement group_id="O3" value="97.3" spread="2.87"/>
                    <measurement group_id="O4" value="96.8" spread="3.32"/>
                    <measurement group_id="O5" value="97.1" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent O2 in blood: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" spread="2.40"/>
                    <measurement group_id="O2" value="96.0" spread="4.00"/>
                    <measurement group_id="O3" value="96.9" spread="2.88"/>
                    <measurement group_id="O4" value="97.7" spread="2.49"/>
                    <measurement group_id="O5" value="96.5" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent O2 in blood: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" spread="2.27"/>
                    <measurement group_id="O2" value="97.9" spread="2.03"/>
                    <measurement group_id="O3" value="96.7" spread="2.41"/>
                    <measurement group_id="O4" value="97.5" spread="2.60"/>
                    <measurement group_id="O5" value="97.3" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent O2 in blood: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="2.06"/>
                    <measurement group_id="O2" value="97.3" spread="2.12"/>
                    <measurement group_id="O3" value="96.3" spread="3.11"/>
                    <measurement group_id="O4" value="97.2" spread="1.99"/>
                    <measurement group_id="O5" value="97.1" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs: Mean Oxygen Saturation (SaO2) Via Pulse Oximetry</title>
        <description>Assessment of SaO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”; for Cohort 2 and 4: “Day 2, pre-dose”, and “Day 3, pre-dose and 24 h”</time_frame>
        <population>All subject population. Data was not collected for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Mean Oxygen Saturation (SaO2) Via Pulse Oximetry</title>
          <description>Assessment of SaO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
          <population>All subject population. Data was not collected for this parameter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs: Mean Level of Positive End Expiratory Pressure</title>
        <description>Assessment of level of positive end expiratory pressure was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”; for Cohort 2 and 4: “Day 2, pre-dose”, and “Day 3, pre-dose and 24 h”</time_frame>
        <population>All subject population. Data was not collected for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Mean Level of Positive End Expiratory Pressure</title>
          <description>Assessment of level of positive end expiratory pressure was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
          <population>All subject population. Data was not collected for this parameter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs: Mean Level of Peak and Plateau Ventilator Pressures</title>
        <description>Assessment of mean level of peak and plateau ventilator pressures was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”; for Cohort 2 and 4: “Day 2, pre-dose”, and “Day 3, pre-dose and 24 h”</time_frame>
        <population>All subject population. Data was not collected for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Mean Level of Peak and Plateau Ventilator Pressures</title>
          <description>Assessment of mean level of peak and plateau ventilator pressures was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
          <population>All subject population. Data was not collected for this parameter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs: Mean Oxygen Requirement (FiO2) Via Pulse Oximetry</title>
        <description>Assessment of mean FiO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
        <time_frame>For Cohort 1 and 3: “Day 1, 4 h”, “Day 2, pre-dose”, “Day 3, pre-dose and 24 h”; for Cohort 2 and 4: “Day 2, pre-dose”, and “Day 3, pre-dose and 24 h”</time_frame>
        <population>All subject population. Data was not collected for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Mean Oxygen Requirement (FiO2) Via Pulse Oximetry</title>
          <description>Assessment of mean FiO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.</description>
          <population>All subject population. Data was not collected for this parameter.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Electrocardiogram (ECG) Parameters Including PR, QRS, QT, and QTcB, QTcF, RR Intervals</title>
        <description>12-lead ECGs were obtained at each timepoint during the study using an ECG machine that automatically calculated the heart rate and measures RR, PR, QRS, QT, and QTc intervals. Absolute mean values of PR, QRS, QT, and QTcB, QTcF, RR intervals were reported.</description>
        <time_frame>Day 2, pre-dose, Day 3, pre-dose, Day 3, 24 h and Follow-up (Day 7)</time_frame>
        <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Electrocardiogram (ECG) Parameters Including PR, QRS, QT, and QTcB, QTcF, RR Intervals</title>
          <description>12-lead ECGs were obtained at each timepoint during the study using an ECG machine that automatically calculated the heart rate and measures RR, PR, QRS, QT, and QTc intervals. Absolute mean values of PR, QRS, QT, and QTcB, QTcF, RR intervals were reported.</description>
          <population>All subject population. Only those participants available at the specified time points were analyzed.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.4" spread="14.35"/>
                    <measurement group_id="O2" value="145.5" spread="21.21"/>
                    <measurement group_id="O3" value="141.5" spread="17.80"/>
                    <measurement group_id="O4" value="143.9" spread="30.54"/>
                    <measurement group_id="O5" value="152.9" spread="20.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.7" spread="20.73"/>
                    <measurement group_id="O2" value="142.0" spread="22.33"/>
                    <measurement group_id="O3" value="141.6" spread="27.43"/>
                    <measurement group_id="O4" value="148.6" spread="23.00"/>
                    <measurement group_id="O5" value="152.0" spread="25.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.0" spread="18.90"/>
                    <measurement group_id="O2" value="146.9" spread="34.15"/>
                    <measurement group_id="O3" value="142.2" spread="24.93"/>
                    <measurement group_id="O4" value="145.9" spread="21.21"/>
                    <measurement group_id="O5" value="160.7" spread="23.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.9" spread="13.85"/>
                    <measurement group_id="O2" value="142.8" spread="24.33"/>
                    <measurement group_id="O3" value="142.0" spread="16.54"/>
                    <measurement group_id="O4" value="138.1" spread="26.91"/>
                    <measurement group_id="O5" value="155.1" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" spread="9.26"/>
                    <measurement group_id="O2" value="86.5" spread="10.78"/>
                    <measurement group_id="O3" value="86.8" spread="12.49"/>
                    <measurement group_id="O4" value="87.2" spread="13.34"/>
                    <measurement group_id="O5" value="88.0" spread="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" spread="9.62"/>
                    <measurement group_id="O2" value="87.1" spread="8.86"/>
                    <measurement group_id="O3" value="89.5" spread="10.66"/>
                    <measurement group_id="O4" value="87.6" spread="14.56"/>
                    <measurement group_id="O5" value="86.5" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="10.48"/>
                    <measurement group_id="O2" value="85.7" spread="7.70"/>
                    <measurement group_id="O3" value="90.6" spread="8.85"/>
                    <measurement group_id="O4" value="88.3" spread="14.36"/>
                    <measurement group_id="O5" value="88.4" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" spread="9.39"/>
                    <measurement group_id="O2" value="86.0" spread="8.42"/>
                    <measurement group_id="O3" value="88.5" spread="11.35"/>
                    <measurement group_id="O4" value="85.4" spread="14.01"/>
                    <measurement group_id="O5" value="85.9" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.7" spread="30.74"/>
                    <measurement group_id="O2" value="349.5" spread="29.89"/>
                    <measurement group_id="O3" value="342.0" spread="61.77"/>
                    <measurement group_id="O4" value="332.1" spread="34.00"/>
                    <measurement group_id="O5" value="365.1" spread="39.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.6" spread="34.99"/>
                    <measurement group_id="O2" value="352.9" spread="36.20"/>
                    <measurement group_id="O3" value="351.3" spread="56.64"/>
                    <measurement group_id="O4" value="342.5" spread="24.15"/>
                    <measurement group_id="O5" value="351.4" spread="48.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.8" spread="35.13"/>
                    <measurement group_id="O2" value="347.4" spread="28.93"/>
                    <measurement group_id="O3" value="340.2" spread="31.64"/>
                    <measurement group_id="O4" value="336.5" spread="31.22"/>
                    <measurement group_id="O5" value="358.0" spread="47.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346.7" spread="33.16"/>
                    <measurement group_id="O2" value="352.5" spread="16.89"/>
                    <measurement group_id="O3" value="335.0" spread="47.41"/>
                    <measurement group_id="O4" value="342.1" spread="37.14"/>
                    <measurement group_id="O5" value="369.1" spread="45.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432.5" spread="28.82"/>
                    <measurement group_id="O2" value="427.5" spread="27.91"/>
                    <measurement group_id="O3" value="422.0" spread="28.72"/>
                    <measurement group_id="O4" value="418.6" spread="21.72"/>
                    <measurement group_id="O5" value="416.2" spread="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.4" spread="27.55"/>
                    <measurement group_id="O2" value="443.4" spread="28.77"/>
                    <measurement group_id="O3" value="414.4" spread="22.33"/>
                    <measurement group_id="O4" value="420.9" spread="26.99"/>
                    <measurement group_id="O5" value="427.4" spread="31.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.8" spread="21.83"/>
                    <measurement group_id="O2" value="425.6" spread="18.45"/>
                    <measurement group_id="O3" value="418.5" spread="22.60"/>
                    <measurement group_id="O4" value="422.5" spread="22.33"/>
                    <measurement group_id="O5" value="429.6" spread="22.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435.5" spread="32.08"/>
                    <measurement group_id="O2" value="439.4" spread="15.30"/>
                    <measurement group_id="O3" value="430.1" spread="43.76"/>
                    <measurement group_id="O4" value="434.7" spread="19.27"/>
                    <measurement group_id="O5" value="440.3" spread="48.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.3" spread="24.07"/>
                    <measurement group_id="O2" value="399.4" spread="22.88"/>
                    <measurement group_id="O3" value="392.6" spread="36.62"/>
                    <measurement group_id="O4" value="387.1" spread="22.19"/>
                    <measurement group_id="O5" value="397.9" spread="24.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.3" spread="27.85"/>
                    <measurement group_id="O2" value="410.5" spread="26.01"/>
                    <measurement group_id="O3" value="391.5" spread="30.90"/>
                    <measurement group_id="O4" value="392.7" spread="21.41"/>
                    <measurement group_id="O5" value="400.0" spread="35.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.4" spread="24.77"/>
                    <measurement group_id="O2" value="397.4" spread="14.85"/>
                    <measurement group_id="O3" value="390.3" spread="22.25"/>
                    <measurement group_id="O4" value="391.4" spread="22.27"/>
                    <measurement group_id="O5" value="403.7" spread="26.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.4" spread="29.35"/>
                    <measurement group_id="O2" value="408.1" spread="11.78"/>
                    <measurement group_id="O3" value="395.5" spread="43.63"/>
                    <measurement group_id="O4" value="401.0" spread="23.91"/>
                    <measurement group_id="O5" value="414.9" spread="45.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: Day 2, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622.0" spread="117.16"/>
                    <measurement group_id="O2" value="677.5" spread="133.48"/>
                    <measurement group_id="O3" value="667.7" spread="219.26"/>
                    <measurement group_id="O4" value="635.5" spread="119.09"/>
                    <measurement group_id="O5" value="780.8" spread="178.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: Day 3, pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640.1" spread="103.46"/>
                    <measurement group_id="O2" value="641.4" spread="137.62"/>
                    <measurement group_id="O3" value="727.9" spread="210.54"/>
                    <measurement group_id="O4" value="670.2" spread="115.37"/>
                    <measurement group_id="O5" value="679.5" spread="140.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: Day 3, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="598.7" spread="99.54"/>
                    <measurement group_id="O2" value="675.1" spread="137.03"/>
                    <measurement group_id="O3" value="665.8" spread="114.27"/>
                    <measurement group_id="O4" value="639.0" spread="106.37"/>
                    <measurement group_id="O5" value="703.1" spread="171.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval: Follow up (Day 7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="639.0" spread="103.45"/>
                    <measurement group_id="O2" value="646.8" spread="74.52"/>
                    <measurement group_id="O3" value="608.3" spread="98.05"/>
                    <measurement group_id="O4" value="622.3" spread="105.38"/>
                    <measurement group_id="O5" value="709.0" spread="112.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE)</title>
        <description>AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</description>
        <time_frame>Up to Follow-up (Day 7)</time_frame>
        <population>All subject population.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE)</title>
          <description>AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</description>
          <population>All subject population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Interleukin-6 Levels</title>
        <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum interleukin-6 levels at these specified time oints were reported.</description>
        <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
        <population>Pharmacodynamic (PD) Population was defined as patients in the ‘All Subjects’ population for whom a pharmacodynamic sample was obtained and analysed (Flow Cytometry data were excluded from the definition of pharmacodynamic sample). Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Interleukin-6 Levels</title>
          <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum interleukin-6 levels at these specified time oints were reported.</description>
          <population>Pharmacodynamic (PD) Population was defined as patients in the ‘All Subjects’ population for whom a pharmacodynamic sample was obtained and analysed (Flow Cytometry data were excluded from the definition of pharmacodynamic sample). Only those participants available at the specified time points were analyzed.</population>
          <units>Picogram per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Since 1st Dose, 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509.44" lower_limit="404.31" upper_limit="641.92"/>
                    <measurement group_id="O2" value="286.17" lower_limit="193.56" upper_limit="423.09"/>
                    <measurement group_id="O3" value="391.09" lower_limit="285.50" upper_limit="535.73"/>
                    <measurement group_id="O4" value="309.57" lower_limit="241.39" upper_limit="397.00"/>
                    <measurement group_id="O5" value="395.09" lower_limit="311.51" upper_limit="501.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516.49" lower_limit="386.08" upper_limit="690.93"/>
                    <measurement group_id="O2" value="315.89" lower_limit="195.60" upper_limit="510.16"/>
                    <measurement group_id="O3" value="362.03" lower_limit="242.29" upper_limit="540.95"/>
                    <measurement group_id="O4" value="348.23" lower_limit="252.52" upper_limit="480.21"/>
                    <measurement group_id="O5" value="310.98" lower_limit="229.12" upper_limit="422.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 18 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.94" lower_limit="342.58" upper_limit="663.98"/>
                    <measurement group_id="O2" value="247.22" lower_limit="143.35" upper_limit="426.37"/>
                    <measurement group_id="O3" value="275.7" lower_limit="174.63" upper_limit="435.27"/>
                    <measurement group_id="O4" value="292.24" lower_limit="202.25" upper_limit="422.28"/>
                    <measurement group_id="O5" value="238.7" lower_limit="167.94" upper_limit="339.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556.06" lower_limit="396.84" upper_limit="779.16"/>
                    <measurement group_id="O2" value="231.1" lower_limit="132.58" upper_limit="402.84"/>
                    <measurement group_id="O3" value="228.1" lower_limit="143.19" upper_limit="363.33"/>
                    <measurement group_id="O4" value="310.47" lower_limit="214.22" upper_limit="449.97"/>
                    <measurement group_id="O5" value="162.82" lower_limit="111.89" upper_limit="236.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.35" lower_limit="227.93" upper_limit="461.57"/>
                    <measurement group_id="O2" value="167.69" lower_limit="93.79" upper_limit="299.85"/>
                    <measurement group_id="O3" value="290.59" lower_limit="175.53" upper_limit="481.08"/>
                    <measurement group_id="O4" value="235.13" lower_limit="158.44" upper_limit="348.94"/>
                    <measurement group_id="O5" value="119.98" lower_limit="75.81" upper_limit="189.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.21" lower_limit="162.45" upper_limit="385.39"/>
                    <measurement group_id="O2" value="165.46" lower_limit="82.36" upper_limit="332.41"/>
                    <measurement group_id="O3" value="184.93" lower_limit="100.25" upper_limit="341.14"/>
                    <measurement group_id="O4" value="182.54" lower_limit="113.18" upper_limit="294.40"/>
                    <measurement group_id="O5" value="106.32" lower_limit="62.32" upper_limit="181.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.79" lower_limit="113.50" upper_limit="297.61"/>
                    <measurement group_id="O2" value="166.87" lower_limit="77.25" upper_limit="360.46"/>
                    <measurement group_id="O3" value="286.79" lower_limit="139.88" upper_limit="587.97"/>
                    <measurement group_id="O4" value="210.87" lower_limit="123.37" upper_limit="360.41"/>
                    <measurement group_id="O5" value="106.32" lower_limit="62.32" upper_limit="181.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.562</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.228</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.357</ci_lower_limit>
            <ci_upper_limit>0.885</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.612</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.281</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.349</ci_lower_limit>
            <ci_upper_limit>1.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.518</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.319</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.274</ci_lower_limit>
            <ci_upper_limit>0.981</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.416</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.326</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.217</ci_lower_limit>
            <ci_upper_limit>0.796</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.517</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.340</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.262</ci_lower_limit>
            <ci_upper_limit>1.021</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.661</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.410</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.291</ci_lower_limit>
            <ci_upper_limit>1.503</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.908</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.454</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.366</ci_lower_limit>
            <ci_upper_limit>2.254</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.768</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.195</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.520</ci_lower_limit>
            <ci_upper_limit>1.134</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.701</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.427</ci_lower_limit>
            <ci_upper_limit>1.150</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.578</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.282</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.329</ci_lower_limit>
            <ci_upper_limit>1.015</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.410</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.287</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.231</ci_lower_limit>
            <ci_upper_limit>0.728</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.896</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.308</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.484</ci_lower_limit>
            <ci_upper_limit>1.657</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.739</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.374</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.350</ci_lower_limit>
            <ci_upper_limit>1.563</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.560</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.431</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.659</ci_lower_limit>
            <ci_upper_limit>3.697</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.608</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.170</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.433</ci_lower_limit>
            <ci_upper_limit>0.853</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.674</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.217</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.437</ci_lower_limit>
            <ci_upper_limit>1.039</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.613</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.247</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.374</ci_lower_limit>
            <ci_upper_limit>1.004</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.558</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.251</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.338</ci_lower_limit>
            <ci_upper_limit>0.921</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.725</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.264</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.427</ci_lower_limit>
            <ci_upper_limit>1.230</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.730</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.321</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.384</ci_lower_limit>
            <ci_upper_limit>1.386</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.359</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.559</ci_lower_limit>
            <ci_upper_limit>2.353</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.776</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.167</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.556</ci_lower_limit>
            <ci_upper_limit>1.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.602</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.212</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.394</ci_lower_limit>
            <ci_upper_limit>0.919</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.623</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.240</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.386</ci_lower_limit>
            <ci_upper_limit>1.007</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.429</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.245</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.263</ci_lower_limit>
            <ci_upper_limit>0.700</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.502</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.259</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.299</ci_lower_limit>
            <ci_upper_limit>0.842</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.479</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.317</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.255</ci_lower_limit>
            <ci_upper_limit>0.903</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.579</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.361</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.281</ci_lower_limit>
            <ci_upper_limit>1.192</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum CXCL8 (Interleuin-8) Levels</title>
        <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum CXCL8 (Interleuin-8) levels at these specified time points were reported.</description>
        <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
        <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum CXCL8 (Interleuin-8) Levels</title>
          <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum CXCL8 (Interleuin-8) levels at these specified time points were reported.</description>
          <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Since 1st Dose, 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.66" lower_limit="29.86" upper_limit="47.50"/>
                    <measurement group_id="O2" value="18.22" lower_limit="12.53" upper_limit="26.50"/>
                    <measurement group_id="O3" value="27.34" lower_limit="19.88" upper_limit="37.60"/>
                    <measurement group_id="O4" value="21.06" lower_limit="16.53" upper_limit="26.84"/>
                    <measurement group_id="O5" value="21.85" lower_limit="17.38" upper_limit="27.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.53" lower_limit="19.86" upper_limit="35.44"/>
                    <measurement group_id="O2" value="18.58" lower_limit="11.42" upper_limit="30.21"/>
                    <measurement group_id="O3" value="21.00" lower_limit="13.88" upper_limit="31.77"/>
                    <measurement group_id="O4" value="22.01" lower_limit="16.00" upper_limit="30.29"/>
                    <measurement group_id="O5" value="17.42" lower_limit="12.89" upper_limit="23.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 18 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.37" lower_limit="15.61" upper_limit="29.26"/>
                    <measurement group_id="O2" value="14.55" lower_limit="8.59" upper_limit="24.67"/>
                    <measurement group_id="O3" value="15.49" lower_limit="9.88" upper_limit="24.28"/>
                    <measurement group_id="O4" value="21.10" lower_limit="14.76" upper_limit="30.16"/>
                    <measurement group_id="O5" value="15.96" lower_limit="11.57" upper_limit="22.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.05" lower_limit="17.63" upper_limit="32.81"/>
                    <measurement group_id="O2" value="16.19" lower_limit="9.61" upper_limit="27.28"/>
                    <measurement group_id="O3" value="15.75" lower_limit="10.10" upper_limit="24.54"/>
                    <measurement group_id="O4" value="22.23" lower_limit="15.79" upper_limit="31.29"/>
                    <measurement group_id="O5" value="15.79" lower_limit="11.48" upper_limit="21.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65" lower_limit="12.30" upper_limit="25.33"/>
                    <measurement group_id="O2" value="16.24" lower_limit="8.85" upper_limit="29.80"/>
                    <measurement group_id="O3" value="19.62" lower_limit="11.55" upper_limit="33.32"/>
                    <measurement group_id="O4" value="21.70" lower_limit="14.54" upper_limit="32.41"/>
                    <measurement group_id="O5" value="13.40" lower_limit="9.19" upper_limit="19.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.99" lower_limit="10.80" upper_limit="23.66"/>
                    <measurement group_id="O2" value="15.09" lower_limit="7.91" upper_limit="28.75"/>
                    <measurement group_id="O3" value="17.19" lower_limit="9.76" upper_limit="30.26"/>
                    <measurement group_id="O4" value="20.61" lower_limit="13.36" upper_limit="31.77"/>
                    <measurement group_id="O5" value="15.47" lower_limit="10.30" upper_limit="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.14" lower_limit="13.65" upper_limit="26.84"/>
                    <measurement group_id="O2" value="17.33" lower_limit="9.99" upper_limit="30.06"/>
                    <measurement group_id="O3" value="26.32" lower_limit="15.58" upper_limit="44.47"/>
                    <measurement group_id="O4" value="33.54" lower_limit="22.92" upper_limit="49.08"/>
                    <measurement group_id="O5" value="14.24" lower_limit="9.81" upper_limit="20.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.484</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.219</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.312</ci_lower_limit>
            <ci_upper_limit>0.750</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.700</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.282</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.399</ci_lower_limit>
            <ci_upper_limit>1.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.681</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.305</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.370</ci_lower_limit>
            <ci_upper_limit>1.254</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.673</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.302</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.368</ci_lower_limit>
            <ci_upper_limit>1.231</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.920</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.351</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.456</ci_lower_limit>
            <ci_upper_limit>1.857</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.944</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.376</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.445</ci_lower_limit>
            <ci_upper_limit>2.002</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.905</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.321</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.476</ci_lower_limit>
            <ci_upper_limit>1.723</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.726</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.199</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.488</ci_lower_limit>
            <ci_upper_limit>1.080</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.791</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.255</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.476</ci_lower_limit>
            <ci_upper_limit>1.317</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.725</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.277</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.417</ci_lower_limit>
            <ci_upper_limit>1.260</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.655</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.273</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.379</ci_lower_limit>
            <ci_upper_limit>1.130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.323</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.583</ci_lower_limit>
            <ci_upper_limit>2.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.346</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>2.146</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.375</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.313</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.735</ci_lower_limit>
            <ci_upper_limit>2.574</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.559</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.168</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.400</ci_lower_limit>
            <ci_upper_limit>0.783</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.830</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.216</dispersion_value>
            <ci_percent>95.000</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>1.277</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.987</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.238</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.613</ci_lower_limit>
            <ci_upper_limit>1.589</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.924</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.231</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.582</ci_lower_limit>
            <ci_upper_limit>1.467</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.230</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.270</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.716</ci_lower_limit>
            <ci_upper_limit>2.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.289</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.292</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.719</ci_lower_limit>
            <ci_upper_limit>2.312</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.752</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.254</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.053</ci_lower_limit>
            <ci_upper_limit>2.916</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.580</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.163</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.419</ci_lower_limit>
            <ci_upper_limit>0.803</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.657</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.209</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.433</ci_lower_limit>
            <ci_upper_limit>0.996</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.747</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.225</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.477</ci_lower_limit>
            <ci_upper_limit>1.171</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.657</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.222</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.421</ci_lower_limit>
            <ci_upper_limit>1.024</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.759</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.261</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.451</ci_lower_limit>
            <ci_upper_limit>1.279</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.968</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.282</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.550</ci_lower_limit>
            <ci_upper_limit>1.701</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.744</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.251</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.450</ci_lower_limit>
            <ci_upper_limit>1.229</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum C-Reactive Protein (CRP) Levels</title>
        <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of serum CRP levels at these specified time points were reported.</description>
        <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
        <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum C-Reactive Protein (CRP) Levels</title>
          <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of serum CRP levels at these specified time points were reported.</description>
          <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Since 1st Dose, 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.62" lower_limit="108.90" upper_limit="140.33"/>
                    <measurement group_id="O2" value="95.60" lower_limit="77.82" upper_limit="117.45"/>
                    <measurement group_id="O3" value="117.68" lower_limit="99.05" upper_limit="139.82"/>
                    <measurement group_id="O4" value="117.42" lower_limit="102.48" upper_limit="134.55"/>
                    <measurement group_id="O5" value="110.88" lower_limit="97.49" upper_limit="126.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.02" lower_limit="117.47" upper_limit="162.17"/>
                    <measurement group_id="O2" value="109.74" lower_limit="84.28" upper_limit="142.88"/>
                    <measurement group_id="O3" value="133.17" lower_limit="106.76" upper_limit="166.11"/>
                    <measurement group_id="O4" value="136.01" lower_limit="114.22" upper_limit="161.96"/>
                    <measurement group_id="O5" value="122.42" lower_limit="103.71" upper_limit="144.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 18 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.10" lower_limit="118.34" upper_limit="175.45"/>
                    <measurement group_id="O2" value="112.06" lower_limit="81.18" upper_limit="154.69"/>
                    <measurement group_id="O3" value="142.96" lower_limit="109.14" upper_limit="187.25"/>
                    <measurement group_id="O4" value="153.76" lower_limit="123.93" upper_limit="190.78"/>
                    <measurement group_id="O5" value="121.97" lower_limit="99.71" upper_limit="149.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.88" lower_limit="125.86" upper_limit="188.14"/>
                    <measurement group_id="O2" value="97.42" lower_limit="70.10" upper_limit="135.38"/>
                    <measurement group_id="O3" value="140.47" lower_limit="106.64" upper_limit="185.04"/>
                    <measurement group_id="O4" value="141.84" lower_limit="114.09" upper_limit="176.33"/>
                    <measurement group_id="O5" value="125.02" lower_limit="101.78" upper_limit="153.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.36" lower_limit="122.11" upper_limit="207.97"/>
                    <measurement group_id="O2" value="105.45" lower_limit="68.22" upper_limit="162.98"/>
                    <measurement group_id="O3" value="105.17" lower_limit="71.94" upper_limit="153.77"/>
                    <measurement group_id="O4" value="138.05" lower_limit="103.11" upper_limit="184.84"/>
                    <measurement group_id="O5" value="92.50" lower_limit="70.13" upper_limit="122.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.03" lower_limit="138.38" upper_limit="231.62"/>
                    <measurement group_id="O2" value="83.21" lower_limit="55.09" upper_limit="125.67"/>
                    <measurement group_id="O3" value="123.58" lower_limit="86.64" upper_limit="176.27"/>
                    <measurement group_id="O4" value="116.27" lower_limit="88.06" upper_limit="153.52"/>
                    <measurement group_id="O5" value="78.55" lower_limit="60.09" upper_limit="102.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.67" lower_limit="126.16" upper_limit="233.62"/>
                    <measurement group_id="O2" value="90.20" lower_limit="55.50" upper_limit="146.58"/>
                    <measurement group_id="O3" value="124.33" lower_limit="80.24" upper_limit="192.64"/>
                    <measurement group_id="O4" value="123.97" lower_limit="88.87" upper_limit="172.95"/>
                    <measurement group_id="O5" value="77.40" lower_limit="55.46" upper_limit="108.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.773</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.121</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.607</ci_lower_limit>
            <ci_upper_limit>0.985</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.795</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.155</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.583</ci_lower_limit>
            <ci_upper_limit>1.084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.778</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.189</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.533</ci_lower_limit>
            <ci_upper_limit>1.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.633</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.193</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.430</ci_lower_limit>
            <ci_upper_limit>0.931</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.662</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.255</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.397</ci_lower_limit>
            <ci_upper_limit>1.103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.465</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.243</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.286</ci_lower_limit>
            <ci_upper_limit>0.756</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.525</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.287</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.295</ci_lower_limit>
            <ci_upper_limit>0.935</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.952</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.768</ci_lower_limit>
            <ci_upper_limit>1.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.965</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.733</ci_lower_limit>
            <ci_upper_limit>1.269</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.992</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.168</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.710</ci_lower_limit>
            <ci_upper_limit>1.387</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.913</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.171</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.649</ci_lower_limit>
            <ci_upper_limit>1.285</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.660</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.233</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.415</ci_lower_limit>
            <ci_upper_limit>1.051</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.690</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.220</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.445</ci_lower_limit>
            <ci_upper_limit>1.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.724</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.268</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.423</ci_lower_limit>
            <ci_upper_limit>1.239</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.950</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.093</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.789</ci_lower_limit>
            <ci_upper_limit>1.144</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.985</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.119</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.777</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.146</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.797</ci_lower_limit>
            <ci_upper_limit>1.428</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.922</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.148</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.686</ci_lower_limit>
            <ci_upper_limit>1.239</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.866</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.198</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.583</ci_lower_limit>
            <ci_upper_limit>1.287</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.649</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.190</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.444</ci_lower_limit>
            <ci_upper_limit>0.950</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.722</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.228</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.457</ci_lower_limit>
            <ci_upper_limit>1.140</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.897</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.091</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.748</ci_lower_limit>
            <ci_upper_limit>1.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.887</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.703</ci_lower_limit>
            <ci_upper_limit>1.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.846</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.638</ci_lower_limit>
            <ci_upper_limit>1.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.812</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.145</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.609</ci_lower_limit>
            <ci_upper_limit>1.084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.580</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.194</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.394</ci_lower_limit>
            <ci_upper_limit>0.855</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.439</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.188</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.301</ci_lower_limit>
            <ci_upper_limit>0.639</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.451</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.230</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.285</ci_lower_limit>
            <ci_upper_limit>0.714</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Endothelial Cell/Neutrophil Interaction: Mean Soluble Tumor Necrosis Factor Receptors-I</title>
        <description>Samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of soluble tumor necrosis factor receptors-I levels at these specified time points were reported.</description>
        <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
        <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Endothelial Cell/Neutrophil Interaction: Mean Soluble Tumor Necrosis Factor Receptors-I</title>
          <description>Samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of soluble tumor necrosis factor receptors-I levels at these specified time points were reported.</description>
          <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Since 1st Dose, 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2457.23" lower_limit="2129.05" upper_limit="2835.99"/>
                    <measurement group_id="O2" value="2089.11" lower_limit="1653.81" upper_limit="2639.00"/>
                    <measurement group_id="O3" value="2240.84" lower_limit="1829.96" upper_limit="2743.98"/>
                    <measurement group_id="O4" value="2046.04" lower_limit="1748.13" upper_limit="2394.72"/>
                    <measurement group_id="O5" value="2267.35" lower_limit="1961.10" upper_limit="2621.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2448.86" lower_limit="2124.10" upper_limit="2823.28"/>
                    <measurement group_id="O2" value="2624.12" lower_limit="2074.37" upper_limit="3319.57"/>
                    <measurement group_id="O3" value="2358.84" lower_limit="1923.30" upper_limit="2893.02"/>
                    <measurement group_id="O4" value="2151.51" lower_limit="1829.23" upper_limit="2530.58"/>
                    <measurement group_id="O5" value="1880.20" lower_limit="1620.96" upper_limit="2180.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 18 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2371.29" lower_limit="2016.83" upper_limit="2788.05"/>
                    <measurement group_id="O2" value="2561.58" lower_limit="1960.37" upper_limit="3347.18"/>
                    <measurement group_id="O3" value="2175.30" lower_limit="1725.14" upper_limit="2742.92"/>
                    <measurement group_id="O4" value="2424.70" lower_limit="2020.77" upper_limit="2909.36"/>
                    <measurement group_id="O5" value="1958.95" lower_limit="1659.12" upper_limit="2312.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2548.08" lower_limit="2198.02" upper_limit="2953.89"/>
                    <measurement group_id="O2" value="2423.76" lower_limit="1898.68" upper_limit="3094.06"/>
                    <measurement group_id="O3" value="2215.77" lower_limit="1793.02" upper_limit="2738.19"/>
                    <measurement group_id="O4" value="2420.75" lower_limit="2053.68" upper_limit="2853.44"/>
                    <measurement group_id="O5" value="1939.82" lower_limit="1664.47" upper_limit="2260.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2466.18" lower_limit="2072.55" upper_limit="2934.58"/>
                    <measurement group_id="O2" value="2263.01" lower_limit="1697.90" upper_limit="3016.21"/>
                    <measurement group_id="O3" value="2814.63" lower_limit="2181.24" upper_limit="3631.93"/>
                    <measurement group_id="O4" value="2388.33" lower_limit="1961.17" upper_limit="2908.52"/>
                    <measurement group_id="O5" value="1925.54" lower_limit="1607.47" upper_limit="2306.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2578.17" lower_limit="2180.51" upper_limit="3048.35"/>
                    <measurement group_id="O2" value="2609.42" lower_limit="1987.30" upper_limit="3426.29"/>
                    <measurement group_id="O3" value="2893.81" lower_limit="2268.96" upper_limit="3690.73"/>
                    <measurement group_id="O4" value="2386.32" lower_limit="1977.80" upper_limit="2879.21"/>
                    <measurement group_id="O5" value="1721.54" lower_limit="1445.26" upper_limit="2050.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2436.04" lower_limit="2035.38" upper_limit="2915.58"/>
                    <measurement group_id="O2" value="2844.48" lower_limit="2133.36" upper_limit="3792.64"/>
                    <measurement group_id="O3" value="3591.89" lower_limit="2729.54" upper_limit="4726.69"/>
                    <measurement group_id="O4" value="2992.91" lower_limit="2441.71" upper_limit="3668.54"/>
                    <measurement group_id="O5" value="2094.76" lower_limit="1720.42" upper_limit="2550.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.850</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.646</ci_lower_limit>
            <ci_upper_limit>1.119</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.138</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.814</ci_lower_limit>
            <ci_upper_limit>1.411</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.157</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.790</ci_lower_limit>
            <ci_upper_limit>1.478</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.951</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.715</ci_lower_limit>
            <ci_upper_limit>1.266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.918</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.168</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.655</ci_lower_limit>
            <ci_upper_limit>1.285</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.160</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.735</ci_lower_limit>
            <ci_upper_limit>1.395</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.169</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>1.640</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.912</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.124</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.713</ci_lower_limit>
            <ci_upper_limit>1.167</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.963</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.123</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.753</ci_lower_limit>
            <ci_upper_limit>1.233</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.917</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.693</ci_lower_limit>
            <ci_upper_limit>1.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.870</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.128</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>1.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.153</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.840</ci_lower_limit>
            <ci_upper_limit>1.550</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.146</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.837</ci_lower_limit>
            <ci_upper_limit>1.505</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.474</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.164</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.063</ci_lower_limit>
            <ci_upper_limit>2.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.833</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.672</ci_lower_limit>
            <ci_upper_limit>1.031</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.879</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.109</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.707</ci_lower_limit>
            <ci_upper_limit>1.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.123</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.800</ci_lower_limit>
            <ci_upper_limit>1.307</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.950</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.111</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.761</ci_lower_limit>
            <ci_upper_limit>1.187</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.968</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.132</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.743</ci_lower_limit>
            <ci_upper_limit>1.262</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.926</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.127</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.718</ci_lower_limit>
            <ci_upper_limit>1.193</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>1.229</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.936</ci_lower_limit>
            <ci_upper_limit>1.613</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 6 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.923</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.102</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.753</ci_lower_limit>
            <ci_upper_limit>1.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 12 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.768</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.103</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.625</ci_lower_limit>
            <ci_upper_limit>0.943</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 18 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.826</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.655</ci_lower_limit>
            <ci_upper_limit>1.042</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 24 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.761</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.106</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.615</ci_lower_limit>
            <ci_upper_limit>0.942</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 48 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.781</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.125</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.608</ci_lower_limit>
            <ci_upper_limit>1.003</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 72 h post first dose</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.668</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.121</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>0.851</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison at 96 h post first dose</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Ratio (Treatment/Placebo)</param_type>
            <param_value>0.860</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.133</dispersion_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.659</ci_lower_limit>
            <ci_upper_limit>1.122</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Lung Epithelial Cell Injury: Mean Myeloperoxidase (MPO) Levels</title>
        <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of MPO levels at these specified time points were reported.</description>
        <time_frame>6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1</time_frame>
        <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Lung Epithelial Cell Injury: Mean Myeloperoxidase (MPO) Levels</title>
          <description>Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of MPO levels at these specified time points were reported.</description>
          <population>PD Population. Only those participants available at the specified time points were analyzed.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Since 1st Dose, 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66792.4" lower_limit="50163.43" upper_limit="88933.88"/>
                    <measurement group_id="O2" value="56739.7" lower_limit="35517.01" upper_limit="90643.64"/>
                    <measurement group_id="O3" value="63552.3" lower_limit="43761.86" upper_limit="92292.66"/>
                    <measurement group_id="O4" value="44668.1" lower_limit="32839.83" upper_limit="60756.75"/>
                    <measurement group_id="O5" value="62108.1" lower_limit="46378.91" upper_limit="83171.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94963.6" lower_limit="67732.71" upper_limit="133142.20"/>
                    <measurement group_id="O2" value="49535.7" lower_limit="27600.02" upper_limit="88905.17"/>
                    <measurement group_id="O3" value="85693.0" lower_limit="52298.94" upper_limit="140409.90"/>
                    <measurement group_id="O4" value="39467.3" lower_limit="26518.49" upper_limit="58739.05"/>
                    <measurement group_id="O5" value="61020.7" lower_limit="41912.35" upper_limit="88840.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 18 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84143.5" lower_limit="61847.22" upper_limit="114477.70"/>
                    <measurement group_id="O2" value="70714.1" lower_limit="42068.42" upper_limit="118865.60"/>
                    <measurement group_id="O3" value="84578.5" lower_limit="55836.68" upper_limit="128115.10"/>
                    <measurement group_id="O4" value="64655.1" lower_limit="44897.15" upper_limit="93107.95"/>
                    <measurement group_id="O5" value="67290.8" lower_limit="48679.72" upper_limit="93017.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104225.0" lower_limit="78979.78" upper_limit="137539.60"/>
                    <measurement group_id="O2" value="70943.1" lower_limit="44906.34" upper_limit="112075.90"/>
                    <measurement group_id="O3" value="112745.0" lower_limit="78188.58" upper_limit="162572.70"/>
                    <measurement group_id="O4" value="59336.2" lower_limit="43636.15" upper_limit="80684.97"/>
                    <measurement group_id="O5" value="71506.9" lower_limit="53769.80" upper_limit="95094.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89181.9" lower_limit="65657.74" upper_limit="121134.40"/>
                    <measurement group_id="O2" value="47338.7" lower_limit="27813.57" upper_limit="80570.53"/>
                    <measurement group_id="O3" value="92324.6" lower_limit="59313.52" upper_limit="143708.00"/>
                    <measurement group_id="O4" value="53458.3" lower_limit="37505.36" upper_limit="76196.80"/>
                    <measurement group_id="O5" value="78699.2" lower_limit="55978.77" upper_limit="110641.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79821.0" lower_limit="57835.74" upper_limit="110163.60"/>
                    <measurement group_id="O2" value="88493.3" lower_limit="53136.78" upper_limit="147375.70"/>
                    <measurement group_id="O3" value="148310.0" lower_limit="97377.15" upper_limit="225884.00"/>
                    <measurement group_id="O4" value="61893.0" lower_limit="43541.25" upper_limit="87979.61"/>
                    <measurement group_id="O5" value="73578.6" lower_limit="52720.51" upper_limit="102688.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Since 1st Dose, 96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70263.5" lower_limit="50596.69" upper_limit="97574.74"/>
                    <measurement group_id="O2" value="108777.0" lower_limit="62959.10" upper_limit="187936.90"/>
                    <measurement group_id="O3" value="78570.3" lower_limit="47261.98" upper_limit="130618.70"/>
                    <measurement group_id="O4" value="84008.1" lower_limit="55950.12" upper_limit="126136.80"/>
                    <measurement group_id="O5" value="69268.3" lower_limit="46791.47" upper_limit="102542.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC0-24)</title>
        <description>Absolute values of the mean AUC 0-24 of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h10minutes [min], 24h45min, 27, 34, 40, 80 h since doing on Day 3).</description>
        <time_frame>For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose)</time_frame>
        <population>Pharmacokinetic (PK) population was defined as patients in the ‘All Subjects’ population for whom a pharmacokinetic sample was obtained and analyzed. Note: Due to some placebo patients PK samples being assayed in error, the above PK population definition was adjusted to also exclude any patient receiving Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC0-24)</title>
          <description>Absolute values of the mean AUC 0-24 of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h10minutes [min], 24h45min, 27, 34, 40, 80 h since doing on Day 3).</description>
          <population>Pharmacokinetic (PK) population was defined as patients in the ‘All Subjects’ population for whom a pharmacokinetic sample was obtained and analyzed. Note: Due to some placebo patients PK samples being assayed in error, the above PK population definition was adjusted to also exclude any patient receiving Placebo.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.222" lower_limit="85.306" upper_limit="124.902"/>
                    <measurement group_id="O2" value="186.326" lower_limit="156.472" upper_limit="221.876"/>
                    <measurement group_id="O3" value="178.807" lower_limit="153.644" upper_limit="208.090"/>
                    <measurement group_id="O4" value="217.862" lower_limit="182.558" upper_limit="259.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.199" lower_limit="92.339" upper_limit="136.331"/>
                    <measurement group_id="O2" value="207.050" lower_limit="172.749" upper_limit="248.163"/>
                    <measurement group_id="O3" value="182.590" lower_limit="156.946" upper_limit="212.425"/>
                    <measurement group_id="O4" value="237.549" lower_limit="197.345" upper_limit="285.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.037" lower_limit="81.444" upper_limit="138.057"/>
                    <measurement group_id="O2" value="211.282" lower_limit="177.858" upper_limit="250.988"/>
                    <measurement group_id="O3" value="188.895" lower_limit="160.977" upper_limit="221.654"/>
                    <measurement group_id="O4" value="230.891" lower_limit="189.316" upper_limit="281.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Average Concentration (Cavg) of SB-681323</title>
        <description>Absolute values of mean Cavg of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).</description>
        <time_frame>For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10minutes [min], 24h 45min, 27, 34, 40, 80 h since doing on Day 3)</time_frame>
        <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Average Concentration (Cavg) of SB-681323</title>
          <description>Absolute values of mean Cavg of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).</description>
          <population>PK Population. Only those participants available at the specified time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.301" lower_limit="3.554" upper_limit="5.204"/>
                    <measurement group_id="O2" value="7.764" lower_limit="6.520" upper_limit="9.245"/>
                    <measurement group_id="O3" value="7.450" lower_limit="6.402" upper_limit="8.670"/>
                    <measurement group_id="O4" value="9.078" lower_limit="7.607" upper_limit="10.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.675" lower_limit="3.847" upper_limit="5.680"/>
                    <measurement group_id="O2" value="8.627" lower_limit="7.198" upper_limit="10.340"/>
                    <measurement group_id="O3" value="7.608" lower_limit="6.539" upper_limit="8.851"/>
                    <measurement group_id="O4" value="9.898" lower_limit="8.223" upper_limit="11.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.418" lower_limit="3.393" upper_limit="5.752"/>
                    <measurement group_id="O2" value="8.803" lower_limit="7.411" upper_limit="10.458"/>
                    <measurement group_id="O3" value="7.871" lower_limit="6.707" upper_limit="9.236"/>
                    <measurement group_id="O4" value="9.620" lower_limit="7.888" upper_limit="11.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of SB-681323</title>
        <description>Absolute values of the Cmax of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).</description>
        <time_frame>For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3)</time_frame>
        <population>PK population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
            <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
            <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of SB-681323</title>
          <description>Absolute values of the Cmax of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).</description>
          <population>PK population. Only those participants available at the specified time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.238" lower_limit="18.235" upper_limit="24.736"/>
                    <measurement group_id="O2" value="8.519" lower_limit="7.098" upper_limit="10.225"/>
                    <measurement group_id="O3" value="38.032" lower_limit="33.317" upper_limit="43.415"/>
                    <measurement group_id="O4" value="10.044" lower_limit="8.375" upper_limit="12.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.830" lower_limit="19.533" upper_limit="26.683"/>
                    <measurement group_id="O2" value="8.842" lower_limit="7.377" upper_limit="10.599"/>
                    <measurement group_id="O3" value="38.697" lower_limit="33.996" upper_limit="44.048"/>
                    <measurement group_id="O4" value="10.382" lower_limit="8.647" upper_limit="12.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.888" lower_limit="18.670" upper_limit="25.661"/>
                    <measurement group_id="O2" value="8.990" lower_limit="7.515" upper_limit="10.755"/>
                    <measurement group_id="O3" value="39.180" lower_limit="34.157" upper_limit="44.943"/>
                    <measurement group_id="O4" value="10.131" lower_limit="8.273" upper_limit="12.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to follow up period (Day 7).</time_frame>
      <desc>All subjects population was used for collection of AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Placebo</title>
          <description>Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1-SB-681323, 3 mg, 4 h</title>
          <description>Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2-SB-681323, 7.5 mg, 24 h</title>
          <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3-SB-681323, 7.5 mg, 4 h</title>
          <description>Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days</description>
        </group>
        <group group_id="E5">
          <title>Cohort 4-SB-681323, 10 mg, 24 h</title>
          <description>Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Quadriplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sputum culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vitamin B complex deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

